US20230414642A1 - Methods of mobilizing marrow infiltrating lymphocytes and uses thereof - Google Patents
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof Download PDFInfo
- Publication number
- US20230414642A1 US20230414642A1 US18/327,429 US202318327429A US2023414642A1 US 20230414642 A1 US20230414642 A1 US 20230414642A1 US 202318327429 A US202318327429 A US 202318327429A US 2023414642 A1 US2023414642 A1 US 2023414642A1
- Authority
- US
- United States
- Prior art keywords
- cells
- mils
- selectin
- composition
- chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract description 38
- 210000004698 lymphocyte Anatomy 0.000 title description 16
- 230000001483 mobilizing effect Effects 0.000 title description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 82
- 201000011510 cancer Diseases 0.000 claims abstract description 40
- 229940123546 E-selectin antagonist Drugs 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 49
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 43
- 210000001185 bone marrow Anatomy 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000000638 stimulation Effects 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 239000013255 MILs Substances 0.000 claims 15
- 108010024212 E-Selectin Proteins 0.000 abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 42
- 238000011282 treatment Methods 0.000 abstract description 40
- 239000002412 selectin antagonist Substances 0.000 abstract description 11
- 208000035475 disorder Diseases 0.000 abstract description 9
- 102000015689 E-Selectin Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 description 52
- 102100023471 E-selectin Human genes 0.000 description 41
- 201000010099 disease Diseases 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 30
- 239000008194 pharmaceutical composition Substances 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 23
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 18
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- PXEZBPFEQYCSGD-CVDXTIKBSA-M sodium (2S)-2-[(2R,3R,4R,5R,6R)-3-acetamido-2-[(1R,2R,3S,5R)-3-ethyl-5-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoate Chemical compound [Na+].CC[C@H]1C[C@H](C[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C([O-])=O)[C@H]2NC(C)=O)[C@@H]1O[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC PXEZBPFEQYCSGD-CVDXTIKBSA-M 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 210000005259 peripheral blood Anatomy 0.000 description 14
- 239000011886 peripheral blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 11
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 125000000262 haloalkenyl group Chemical group 0.000 description 10
- 125000001188 haloalkyl group Chemical group 0.000 description 10
- 125000000232 haloalkynyl group Chemical group 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 102100033467 L-selectin Human genes 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 125000005630 sialyl group Chemical group 0.000 description 6
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 5
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- -1 disintegrators Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007915 intraurethral administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001069913 Bos taurus Growth-regulated protein homolog beta Proteins 0.000 description 1
- 108010086884 CTCE-0021 Proteins 0.000 description 1
- 108010048913 CTCE-0214 Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 208000035155 Mitochondrial DNA-associated Leigh syndrome Diseases 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000692850 Sophora cassioides Species 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000003531 maternally-inherited Leigh syndrome Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108010086335 methionine stromal cell-derived factor-1beta Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present disclosure relates to methods for mobilizing tumor-specific, primed, marrow infiltrating lymphocytes (MILs) from the bone marrow using at least one E-selectin antagonist or compositions comprising the same as well as methods of treatment or prevention of cancers using the mobilized MILs.
- MILs tumor-specific, primed, marrow infiltrating lymphocytes
- ACT Adoptive T-cell Therapy
- ACT involves the isolation and ex vivo expansion of tumor specific T-cells to achieve greater number of T-cells than what could be obtained by vaccination alone.
- the tumor specific T-cells are then infused into patients with cancer in an attempt to give their immune system the ability to overwhelm remaining tumor via T-cells which can attack and kill cancer. Therefore, efficacious ACT requires the ability to activate tumor-specific T-cells that have the ability to travel to the tumor site and effectively kill their target.
- T-cells that are able to effectively identify and/or attack cancer cells are of particular interest because, for example, they can allow the body to quickly mount a response to cancer. T-cells that have long life spans are also of particular interest because, for example, they will be able to provide the body with longer-lasting defenses.
- MILs are T-cells that have been primed to tumor antigens. MILs have been found in patients suffering from hematological malignancies and in metastatic disease arising from solid tumors such as prostate, breast, and lung cancers. The presence of tumor-specific T-cells in the bone marrow of patients with hematologic malignancies and solid tumors opens up the prospect of utilizing MILs for many therapies including adoptive T-cell therapy (ACT).
- ACT adoptive T-cell therapy
- MILs have several fundamental properties, making them good candidates for cancer treatments.
- ACT provides one option for cancer treatments, it requires ex vivo expansion of the cells, which can be time-consuming, inconvenient to patients, and labor intensive.
- FIG. 1 A is an exemplary graph of the percentage of CD8+ lymphocytes in the population of CD62L+CD44 ⁇ (na ⁇ ve) lymphocytes found in bone marrow and peripheral blood samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, granulocyte-colony stimulating factor (G-CSF), or saline.
- G-CSF granulocyte-colony stimulating factor
- FIG. 1 B is an exemplary graph of the percentage of CD8+ lymphocytes in the population of CD62L+CD44+ (central memory or CM) lymphocytes found in bone marrow and peripheral blood samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, G-CSF, or saline.
- CD62L+CD44+ central memory or CM lymphocytes found in bone marrow and peripheral blood samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, G-CSF, or saline.
- FIG. 1 C is an exemplary graph of the percentage of CD8+ lymphocytes in the population of CD62L-CD44+(effector memory or EM) lymphocytes found in bone marrow and peripheral blood samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, G-CSF, or saline.
- FIG. 2 is an exemplary graph of the percentage of IFN+ lymphocytes in the population of CD8+ lymphocytes from bone marrow samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, G-CSF, or saline.
- FIG. 3 is an exemplary graph of the percentage of IFN+ lymphocytes in the population of CD8+ lymphocytes from peripheral blood samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, G-CSF, or saline.
- E-selectin (CD62E) is a cell adhesion molecule that is expressed on activated endothelial cells and plays an important role in leukocyte recruitment to the site of injury.
- E-selectin antagonist means an agent that inhibits an activity of E-selectin or inhibits the binding of E-selectin to one or more E-selectin ligands (which in turn may inhibit a biological activity of E-selectin).
- E-selectin antagonist includes antagonists of E-selectin only, as well as antagonists of E-selectin and either P-selectin or L-selectin, and antagonists of E-selectin, P-selectin, and L-selectin.
- E-selectin antagonists include the glycomimetic compounds described herein that inhibit interaction of E-selectin with sialyl Le a (sLe a ) or sialyl Le x (sLe x ).
- E-selectin antagonists also include antibodies, polypeptides, peptides, peptidomimetics, and aptamers which bind at or near the binding site on E-selectin to inhibit E-selectin interaction with sialyl Le a (sLe a ) or sialyl Le x (sLe x )).
- non-glycomimetic moiety includes moieties having a structure not intended to mimic a carbohydrate molecule.
- a non-glycomimetic moiety may not be (and is typically not) active as an E-selectin antagonist.
- non-glycomimetic moieties are generally moieties added to a glycomimetic moiety for purposes of altering at least one property, such as solubility, bio-availability, lipophilicity and/or other drug-like properties of the glycomimetic.
- patient refers to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein.
- the patient, subject or individual is a human.
- the term “therapy” refers to “treating” or “treatment” of a disease or condition including inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease). “Therapy” may also refer to prophylactic treatment, which includes preventing or delaying the onset of the disease or condition from occurring in a subject that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease.
- treatment means the slowing down, interruption, arrest, reversal, or stoppage of the progression of the disease, which does not necessarily require the complete elimination of all the signs and symptoms of the disease.
- Treatment also includes prophylactic treatment to prevent or delay the onset of the disease or condition from occurring in a subject that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease.
- Treatment further means preventing or delaying the relapse or recurrence of the disease or condition in a subject that is considered in remission for the disease or condition.
- treatment is intended to mean that a statistically significant proportion of patients can be treated effectively, in such a way that the symptoms and clinical signs show at least an improvement.
- the person skilled in the art can easily establish whether the proportion is statistically significant using various statistical methods (e.g. confidence intervals, determination of them p value, Student's t-test, Mann-Whitney test etc.). Confidence intervals have a confidence of at least 90%, at least 95%, at least 97%, at least 98% or at least 99%.
- the p values are 0.1, 0.05, 0.01, 0.005 or 0.0001.
- prevention of relapse refers to the reduction of the risk of the return of a disease or condition and/or extending the time until a relapse occurs.
- the agents are administered concurrently. They can be administered in the same composition or in separate compositions.
- “sequentially” is used herein to mean that the gap between administering one agent and the other is significant, i.e., the first administered agent may no longer be present in the bloodstream in a therapeutic amount when the second agent and/or third agent is administered.
- the compounds may be administered in any order.
- agents that are E-selectin antagonists are E-selectin antagonists, compositions comprising the agents, and methods for using the agents for mobilizing marrow infiltrating lymphocytes from the bone marrow.
- Glycomimetic compounds that may be used in these methods are E-selectin antagonists as described herein. Additionally, compounds disclosed herein may be heterobifunctional, for example, an E-selectin antagonist linked to a CXCR4 chemokine receptor antagonist.
- E-selectin is an adhesion molecule expressed on endothelial cells and binds to specific carbohydrate sequences (sialyl Le x and sialyl Le a ) found on the surfaces of opposing bound cells.
- the endothelium in most of the normal vasculature does not express E-selectin until stimulation of protein synthesis by inflammatory mediators. After about three hours of de novo protein synthesis, E-selectin is then expressed as a result of an inflammatory response. In contrast, E-selectin is constitutively expressed in the bone marrow by the endothelial cells lining the blood vessels.
- MILs reside in the vasculature niche of the bone marrow by binding to adhesion molecules, including E-selectin.
- antagonists of E-selectin are provided that mobilize MILs from the bone marrow.
- Such antagonists may include but are not limited to small molecules, antibodies, aptamers, peptides, and glycoproteins.
- MILs derived from mobilized cells from the bone marrow have a wide range of therapeutic uses. For example, MILs can be induced to leave the marrow and distribute to the periphery where they may act in vivo or where they can be collected for ex vivo manipulation such as engineering CAR T-cells.
- a method for mobilizing MILs by inhibiting E-selectin, a major adhesion protein in the bone marrow vasculature may comprise using the at least one E-selectin antagonist alone or in combination with other agents used to mobilize hematopoietic stem cells.
- E-selectin antagonists include E-selectin, a major adhesion protein in the bone marrow vasculature.
- At least one E-selectin antagonist is administered to a patient. In some embodiments, at least one E-selectin antagonist is administered to a cancer patient in remission. In some embodiments, at least one E-selectin antagonist is administered as a cancer vaccine to stimulate MILs in a cancer patient or cancer survivor to prevent relapse.
- a method of treating cancer and/or preventing a cancer relapse comprising administering to a patient at least one E-selectin antagonist in an amount sufficient to mobilize MILs of the patient into the peripheral blood.
- a method of treating cancer and/or preventing a cancer relapse comprising administering to a donor patient at least one E-selectin antagonist in an amount of sufficient to mobilize MILs of the patient out of the marrow (e.g., into the peripheral blood), recovering MILS (e.g., recovering them from the peripheral blood), and transplanting at least a portion of the MIL cell population to the donor patient or another patient.
- the MIL cell population is expanded ex vivo before transplantation.
- a method of preventing cancer comprising administering to a donor patient at least one E-selectin antagonist in an amount sufficient to mobilize MILs of the patient out of the bone marrow (e.g., into the peripheral blood), recovering MILs (e.g., recovering them from the peripheral blood), and transplanting at least a portion of MIL cell population to a subject (e.g., a non-cancer patient, a patient suffering from a different form or type of cancer than the donor patient, etc.).
- the MIL cell population is expanded ex vivo before transplantation.
- the at least one E-selectin antagonist is in the form of a pharmaceutical composition.
- the pharmaceutical composition further comprises at least one pharmaceutically acceptable ingredient.
- At least one E-selectin antagonist may be chosen from glycomimetics.
- at least one E-selectin antagonist is chosen from sialyl Lewis x (sLe x ) and sLe x mimetics.
- at least one E-selectin antagonist is chosen from glycomimetic antagonists of E-selectin, antibodies directed to E-selectin, aptamers to E-selectin, peptides or polypeptides directed to E-selectin, and peptidomimetics directed to E-selectin.
- a colony stimulating factor is administered with at least one E-selectin antagonist to the cancer patient.
- the cancer patient has received or will receive chemotherapy and/or radiotherapy.
- the chemotherapy comprises administration of bortexomib and/or gemcitabine.
- the cancer is a hematologic cancer.
- the cancer is a solid cancer.
- the cancer is a liquid cancer.
- the patient has been diagnosed with a first type of cancer and the cancer for which the method is performed to treat or prevent is a second type of cancer.
- composition comprising MILs mobilized out of the bone marrow by at least one E-selectin antagonist is disclosed.
- treatment of cancer is provided by the mobilization of MILs following the administration of at least one E-selectin antagonist (i.e., in vivo mobilization of MILs).
- relapse of cancer is prevented by the mobilization of MILs following the administration of at least one E-selectin antagonist.
- At least one E-selectin antagonist is chosen from compounds of Formula (I):
- At least one E-selectin antagonist is chosen from compounds of Formula (I), wherein M is a non-glycomimetic moiety comprising polyethylene glycol, thiazolyl, or chromenyl. In some embodiments, at least one E-selectin antagonist is chosen from compounds of Formula (I), wherein M is a non-glycomimetic moiety comprising polyethylene glycol.
- At least one E-selectin antagonist is chosen from compounds of Formula (I), wherein the non-glycomimetic moiety comprises polyethylene glycol.
- At least one E-selectin antagonist is chosen from compounds of Formula (II):
- At least one E-selectin antagonist is chosen from compounds of Formula (IIa):
- the linker groups of Formula I and/or Formula II are independently chosen from groups comprising spacer groups, such spacer groups as, for example, —(CH 2 ) p — and —O(CH 2 ) p —, wherein p is chosen from integers ranging from 1 to 30. In some embodiments, p is chosen from integers ranging from 1 to 20.
- spacer groups include carbonyl groups and carbonyl-containing groups such as, for example, amide groups.
- a non-limiting example of a spacer group is
- the linker groups are independently chosen from
- linker groups such as, for example, polyethylene glycols (PEGs) and —C( ⁇ O)—NH—(CH 2 ) p —C( ⁇ O)—NH—, wherein p is chosen from integers ranging from 1 to 30, or wherein p is chosen from integers ranging from 1 to 20, will be familiar to those of ordinary skill in the art and/or those in possession of the present disclosure.
- PEGs polyethylene glycols
- p is chosen from integers ranging from 1 to 30, or wherein p is chosen from integers ranging from 1 to 20
- At least one linker group is
- At least one linker group is
- At least one linker group is chosen from —C( ⁇ O)NH(CH 2 ) 2 NH—, —CH 2 NHCH 2 —, and —C( ⁇ O)NHCH 2 —. In some embodiments, at least one linker group is —C( ⁇ O)NH(CH 2 ) 2 NH—.
- At least one E-selectin antagonist is chosen from compounds of Formula (Ia):
- n is chosen from integers ranging from 1 to 100. In some embodiments, n is chosen from 4, 8, 12, 16, 20, 24, and 28.
- At least one E-selectin antagonist is chosen from E-selectin antagonists disclosed in U.S. Pat. No. 9,109,002, which is hereby incorporated by reference.
- at least one E-selectin antagonist is GMI-1271. See, e.g., Price et al., “Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone,” Science Translational Medicine, Vol.
- At least one E-selectin antagonist is chosen from compounds of the following Formulae:
- At least one E-selectin antagonist is chosen from compounds of the following Formulae:
- At least one E-selectin antagonist is chosen from E-selectin antagonists disclosed in U.S. Pat. No. 8,410,066 and PCT/US2015/063191, which are hereby incorporated by reference.
- at least one E-selectin antagonist is GMI-1359. See, e.g., Steele, Maria M. et al., “A small molecule glycomimetic antagonist of E-selectin and CXCR4 (GMI-1359) prevents pancreatic tumor metastasis and improves chemotherapy [abstract],” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015 Apr.
- compositions comprising at least one compound of formula (I) and/or formula (II). Such pharmaceutical compositions are described in greater detail herein. These compounds and compositions may be used in the methods described herein.
- At least one E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II))
- at least one E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- At least one E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II))
- the cancer may be a cancer in which the cancer cells may leave the primary site.
- a primary site may be, for example, solid tissue (e.g., breast, prostate, or pancreatic) or the bloodstream.
- MILs may be needed, for example, after high-dose chemotherapy treatment.
- a compound described herein may be used, for example, to release MILs into circulating blood and enhance retention of MILs in the blood.
- the method may include a further step of collecting MILs that are released.
- a variety of techniques are known in the art for collecting MILs that have been released into the blood. For example, apheresis may be utilized.
- the release of MILs from bone marrow into circulating blood and retention therein has a variety of uses.
- the mobilized MILs may be collected from the blood.
- a use of such collected cells is to obtain healthy MILs from an individual prior to treatment of the individual in a manner such that MILs are suppressed.
- the individual can receive a transplantation utilizing MILs collected prior to treatment. This is useful, for example, where an individual needs to be subjected to a chemotherapy protocol that may damage MILs.
- an individual with at least one (i.e., one or more) colony stimulating factor.
- a factor may be administered, for example, before or simultaneous with administration of at least one of the above-described compounds. Where administration is simultaneous, the combination may be administered from a single container or two (or more) separate containers.
- An example of a suitable colony stimulating factor is G-CSF.
- G-CSF induces the bone marrow to grow and produce more stem cells.
- a compound described herein aids in releasing MILs into circulating blood. MILs produced in bone marrow and released into circulating blood, as a result of the combination of the administration (separately or together) of a compound described herein and G-CSF, may be collected as described above. Such collected MILs may be, for example, administered to the individual after chemotherapy.
- Application of a compound described herein to mobilization and harvesting of healthy MILs from bone marrow treated with G-CSF provides cells useful, for example, for transplantation.
- At least one E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II))
- at least one additional chemotherapy agent such as gemcitabine is administered to the individual.
- At least one E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- a pharmaceutical composition comprising at least one compound of E-selectin antagonist (e.g., a compound of formula (I) or formula (II))
- E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- an inflammatory disease in which the adhesion or migration of cells occurs in the disease.
- inflammatory diseases include inflammatory skin disorders such as atopic dermatitis and psoriasis.
- the treatment may reduce (partially or totally) the disease or a complication associated therewith, such as pain.
- the treatment may be used in conjunction with one or more other therapies for such an inflammatory disease or a complication associated therewith.
- At least one E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II))
- at least one E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- the methods and E-selectin antagonists described herein are therefore useful for treating hematologic malignancies and metastatic disease, particularly in combination or as an adjunct therapy with chemotherapy and/or radiation therapy.
- At least one E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II))
- at least one E-selectin antagonist e.g., a compound of formula (I) or formula (II)
- Such agents include, for example, G-CSF; AMD-3100 or other CXCR4 antagonists; GRO- ⁇ (CXCL2) and an N-terminal 4-amino truncated form (SB-251353); IL-8SDF-1a peptide analogs, CTCE-0021 and CTCE-0214; and the SDF1 analog, Met-SDF-1 ⁇ (see, e.g., Pelus, supra and references cited therein).
- the appropriate therapeutic regimen for administering at least one E-selectin antagonist in combination with another mobilizing agent or agents can be readily determined by a person skilled in the clinical art.
- the subject is a human or non-human animal.
- a subject in need of the treatments described herein may exhibit symptoms or sequelae of cancer disease, disorder, or condition described herein or may be at risk of developing the disease, disorder, or condition.
- Non-human animals that may be treated include mammals, for example, non-human primates (e.g., monkey, chimpanzee, gorilla, and the like), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, swine (e.g., pig, miniature pig), equine, canine, feline, bovine, and other domestic, farm, and zoo animals.
- a compound, agent, or composition described herein in treating or preventing a disease or disorder or condition, and determining and adjusting an appropriate dosing regimen (e.g., adjusting the amount of compound per dose and/or number of doses and frequency of dosing), can readily be determined by a person of ordinary skill in the medical and clinical arts.
- One or any combination of diagnostic methods, including physical examination, assessment and monitoring of clinical symptoms, and performance of analytical tests and methods described herein, may be used for monitoring the health status of the subject.
- MILs Mobilization of MILs can be monitored using methods and techniques routinely practiced in the art the skilled person.
- MILs may be identified by identifying the presence or absence of certain cell surface markers.
- the presence and level of MILs can be determined by methods that detect the presence of CD8 or CD4 on the surface of cells (i.e., CD8+ or CD4+ cells).
- the compounds described herein may be formulated in a pharmaceutical composition for use in medicaments and therapeutics for mobilizing MILs and for treatment or preventive (or prophylactic) treatment (e.g., reducing the likelihood of occurrence or of exacerbation of a disease, or of one or more symptoms of the disease) of a disease or disorder for which mobilizing MILs is beneficial or for which receiving a MILs transplant or replacement is beneficial.
- a pharmaceutical composition for use in medicaments and therapeutics for mobilizing MILs and for treatment or preventive (or prophylactic) treatment (e.g., reducing the likelihood of occurrence or of exacerbation of a disease, or of one or more symptoms of the disease) of a disease or disorder for which mobilizing MILs is beneficial or for which receiving a MILs transplant or replacement is beneficial.
- an E-selectin antagonist described herein may depend upon the subject's condition, that is, stage of the disease, severity of symptoms caused by the disease, general health status, as well as age, gender, and weight, and other factors apparent to a person of ordinary skill in the medical art. Similarly, the dose of the therapeutic for treating a disease or disorder may be determined according to parameters understood by a person of ordinary skill in the medical art.
- compositions may be administered in a manner appropriate to the disease or disorder to be treated as determined by persons of ordinary skill in the medical arts.
- An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as discussed herein, including the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration.
- an appropriate dose (or effective dose) and treatment regimen provides the pharmaceutical composition(s) as described herein in an amount sufficient to provide therapeutic and/or prophylactic benefit (for example, an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity or other benefit as described in detail above).
- compositions described herein may be administered to a subject in need thereof by any one of several routes that effectively deliver an effective amount of the compound.
- Such administrative routes include, for example, topical, oral, nasal, intrathecal, enteral, buccal, sublingual, transdermal, rectal, vaginal, intraocular, subconjunctival, sublingual or parenteral administration, including subcutaneous, intravenous, intramuscular, intrasternal, intracavernous, intrameatal or intraurethral injection or infusion.
- routes of administration include, for example, topical, oral, nasal, intrathecal, enteral, buccal, sublingual, transdermal, rectal, vaginal, intraocular, subconjunctival, sublingual or parenteral administration, including subcutaneous, intravenous, intramuscular, intrasternal, intracavernous, intrameatal or intraurethral injection or infusion.
- a pharmaceutical composition may be a sterile aqueous or sterile non-aqueous solution, suspension or emulsion, which additionally comprises a physiologically acceptable excipient (pharmaceutically acceptable or suitable excipient or carrier) (i.e., a non-toxic material that does not interfere with the activity of the active ingredient).
- a physiologically acceptable excipient pharmaceutically acceptable or suitable excipient or carrier
- Such compositions may be in the form of a solid, liquid, or gas (aerosol).
- compositions described herein may be formulated as a lyophilizate, or compounds and polypeptides or peptides described herein may be encapsulated within liposomes using technology known in the art.
- Pharmaceutical compositions may also contain other components, which may be biologically active or inactive.
- Such components include, but are not limited to, buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione, stabilizers, dyes, flavoring agents, and suspending agents and/or preservatives.
- buffers e.g., neutral buffered saline or phosphate buffered saline
- carbohydrates e.g., glucose, mannose, sucrose or dextrans
- mannitol e.glycine
- proteins e.g., polypeptides or amino acids
- polypeptides or amino acids such as glycine
- antioxidants e.g., glycine
- chelating agents such as EDTA or glutathione
- stabilizers e.g.,
- excipients or carriers Any suitable excipient or carrier known to those of ordinary skill in the art for use in pharmaceutical compositions may be employed in the compositions described herein.
- Excipients for therapeutic use are well known, and are described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).
- the type of excipient is selected based on the mode of administration, as well as the chemical composition of the active ingredient(s).
- compositions may be formulated for any appropriate manner of administration, including, for example, topical, oral, nasal, intrathecal, enteral, buccal, sublingual, transdermal, rectal, vaginal, intraocular, subconjunctival, sublingual or parenteral administration, including subcutaneous, intravenous, intramuscular, intrasternal, intracavernous, intrameatal or intraurethral injection or infusion.
- the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer.
- any of the above excipients or a solid excipient or carrier such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, kaolin, glycerin, starch dextrins, sodium alginate, carboxymethylcellulose, ethyl cellulose, glucose, sucrose and/or magnesium carbonate, may be employed.
- a pharmaceutical composition may be in the form of a liquid.
- a liquid pharmaceutical composition may include, for example, one or more of the following: a sterile diluent such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils that may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents; antioxidants; chelating agents; buffers and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- a parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. The use of physiological saline is preferred, and an injectable pharmaceutical composition is preferably sterile.
- At least one E-selectin antagonist described herein can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with any one or more conventional additives, disintegrators, lubricants, and if desired, diluents, buffering agents, moistening agents, preservatives, coloring agents, and flavoring agents.
- the compositions may be formulated to include a buffering agent to provide for protection of the active ingredient from low pH of the gastric environment and/or an enteric coating.
- a composition may be formulated for oral delivery with a flavoring agent, e.g., in a liquid, solid or semi-solid formulation and/or with an enteric coating.
- Oral formulations may be provided as gelatin capsules, which may contain the active compound or biological along with powdered carriers. Similar carriers and diluents may be used to make compressed tablets. Tablets and capsules can be manufactured as sustained release products to provide for continuous release of active ingredients over a period of time. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
- a pharmaceutical composition may be formulated for sustained or slow release.
- Such compositions may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site.
- Sustained-release formulations may contain the active therapeutic dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane. Excipients for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. The amount of active therapeutic contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release, and the nature of the condition to be treated or prevented.
- compositions described herein can be formulated as suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases.
- bases such as emulsifying bases or water-soluble bases.
- the pharmaceutical compositions may be prepared as aerosol formulations to be administered via inhalation.
- the compositions may be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen and the like.
- Topical formulations may be in the form of a transdermal patch, ointment, paste, lotion, cream, gel, and the like. Topical formulations may include one or more of a penetrating agent or enhancer (also call permeation enhancer), thickener, diluent, emulsifier, dispersing aid, or binder.
- Physical penetration enhancers include, for example, electrophoretic techniques such as iontophoresis, use of ultrasound (or “phonophoresis”), and the like.
- Chemical penetration enhancers are agents administered either prior to, with, or immediately following administration of the therapeutic, which increase the permeability of the skin, particularly the stratum corneum, to provide for enhanced penetration of the drug through the skin. Additional chemical and physical penetration enhancers are described in, for example, Transdermal Delivery of Drugs, A. F. Kydonieus (ED) 1987 CRL Press; Percutaneous Penetration Enhancers, eds. Smith et al. (CRC Press, 1995); Lenneras et al., J. Pharm. Pharmacol. 54:499-508 (2002); Karande et al., Pharm. Res. 19:655-60 (2002); Vaddi et al., Int. J. Pharm.
- Routes of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, intrathecal, and subcutaneous routes.
- the compounds or compositions are administered locally (i.e., near a cancer tumor).
- one or more of the compounds or compositions are administered using different routes of administration.
- the compounds or pharmaceutical composition(s) can be administered in one or more doses and treatment regimens, which may be the same or different.
- each of the compounds or pharmaceutical composition(s) is administered in an amount ranging from about 1 mg/kg to about 50 mg/kg once a day.
- the dosage may be at any dosage including, but not limited to, about 1 ⁇ g/kg, 25 ⁇ g/kg, 50 ⁇ g/kg, 75 ⁇ g/kg, 100 ⁇ g/kg, 125 ⁇ g/kg, 150 ⁇ g/kg, 175 ⁇ g/kg, 200 ⁇ g/kg, 225 ⁇ g/kg, 250 ⁇ g/kg, 275 ⁇ g/kg, 300 ⁇ g/kg, 325 ⁇ g/kg, 350 ⁇ g/kg, 375 ⁇ g/kg, 400 ⁇ g/kg, 425 ⁇ g/kg, 450 ⁇ g/kg, 475 ⁇ g/kg, 500 ⁇ g/kg, 525 ⁇ g/kg, 550 ⁇ g/kg, 575 ⁇ g/kg, 600 ⁇ g/kg, 625 ⁇ g/kg, 650 ⁇ g/kg, 675 ⁇ g/kg, 700 ⁇ g/kg, 725 ⁇ g/kg, 750 ⁇ g/kg, 7
- the compounds or pharmaceutical composition(s) are administered in any of these amounts and ranges once a day, more than once a day, every other day, every two days, etc.
- One of more treatment cycles may be repeated, and any number of cycles is contemplated.
- the number of treatments per day and the amount per dose for each compound or pharmaceutical composition may vary during each cycle.
- Kits with unit doses of one or more of the compounds, polypeptides, peptides, aptamers, antibodies and antigen binding fragments thereof described herein, usually in oral or injectable doses are provided.
- Such kits may include a container containing the unit dose, an informational package insert describing the use and attendant benefits of the therapeutic in treating the pathological condition of interest, and optionally an appliance or device for delivery of the composition.
- GMI-1271 (100% parent, >97% purity) was obtained as a white, crystalline substance. It was stored protected from light at ⁇ 20° C. The compound was formulated in sterile phosphate buffered saline (PBS), resulting in a clear, colorless solution with a pH value of 7.4 and a concentration of 4 mg/mL. The dosing solution was prepared 12 hours prior to the first dose and stored at 4° C. protected from light between treatments.
- PBS sterile phosphate buffered saline
- GMI-1359 (100% parent, >97% purity) was obtained as a white, granular powder. It was stored protected from light at ⁇ 20° C. The compound was formulated in sterile (PBS), resulting in a clear, colorless solution with a pH value of 9.2 and a concentration of 4 mg/mL. The dosing solution was prepared 12 hours prior to the first dose and stored at 4° C. protected from light between treatments.
- PBS sterile
- G-CSF (0.3 mg/mL) was obtained as a clear, colorless stock solution. It was stored protected from light and at 4° C.
- the dosing solution was prepared by diluting the stock solution with 5% dextrose. The result was a clear, colorless solution with a pH value of 4.8 and a concentration of 0.0128 mg/mL.
- the dosing formulation was prepared daily and was stored at room temperature and protected from light, between treatments.
- Anti-CTLA-4 (7.36 mg/mL) was obtained as a clear, colorless stock solution. It was stored protected from light and at 4° C.
- the dosing solution was prepared by diluting the stock solution with PBS. The result was a clear, colorless solution with a pH value of 7 and a concentration of 1 mg/mL.
- the dosing formulation was prepared fresh weekly and stored at 4° C. and protected from light between treatments.
- mice Female Envigo Balb/c mice (BALB/cAnNHsd) were used in this study. They were 6-7 weeks old on Day 1 of the experiment. The animals were fed irradiated Harlan 2918.15 Rodent Diet and water ad libitum. Animals were housed in Innovive disposable ventilated caging with corn cob bedding inside Biobubble® Clean Rooms that provide H.E.P.A filtered air into the bubble environment at 100 complete air changes per hour. All treatments, body weight determinations, and tumor measurements were carried out in the bubble environment. The environment was controlled to a temperature range of 70° ⁇ 2° F. and a humidity range of 30-70%.
- CT26WT cells were obtained. They were grown in RPMI 1640 medium which was modified with 1% 100 mM Na pyruvate, 1% 1 M HEPES buffer, 1% of a 45% glucose solution and supplemented with 10% non-heat-inactivated Fetal Bovine Serum (FBS) and 1% 100 ⁇ Penicillin/Streptomycin/L-Glutamine (PSG). The growth environment was maintained in an incubator with a 5% CO2 atmosphere at 37° C.
- FBS non-heat-inactivated Fetal Bovine Serum
- PSG Penicillin/Streptomycin/L-Glutamine
- the cells (passage 3) were trypsinized using 0.25% trypsin-EDTA solution following cell detachment, the trypsin was inactivated by dilution with complete growth medium and any clumps of cells were separated by pipetting.
- the cells were centrifuged at 200 rcf for 8 minutes at 4° C., the supernatant was aspirated, and the pellet was re-suspended in cold Dulbecco's Phosphate Buffered Saline (DPBS) by pipetting.
- DPBS cold Dulbecco's Phosphate Buffered Saline
- An aliquot of the homogeneous cell suspension was diluted in a trypan blue solution and counted using a Luna automated cell counter. The pre-implantation cell viability was 93%.
- the cell suspension was centrifuged at 200 rcf for 8 minutes at 4° C. The supernatant was aspirated and the cell pellet was re-suspended in cold serum-free medium to generate a final concentration of 2.50E+06 trypan-excluding cells/mL. The cell suspension was maintained on wet ice during implantation.
- Test animals in were implanted subcutaneously, high in the axilla (just under the fore limb) on Day 0 with 5.0E+05 cells in 0.2 mL of serum-free medium using a 27-gauge needle and syringe.
- GMI-1271 is a potent, small-molecule, glycomimetic antagonist of E-selectin.
- GMI-1359 is a potent, small-molecule glycomimetic dual antagonist, targeting E-selectin and CXCR4.
- the effects of inhibiting either E-selectin with GMI-1271 or E-selectin and CXCR4 with GMI-1359 on MIL mobilization was tested in BALB/c mice that had been induced to reject the syngeneic CT26 colon carcinoma via anti-CTLA-4 T cell checkpoint antibody.
- the experimental protocol is summarized in Table 1.
- mice without tumors following CTLA-4 treatment were distributed into the four “Tumor Immune” treatment groups indicated in Table 1 such that the mean body weight within each group was within 10% of the overall mean.
- Treatment for “Tumor Immune” groups 1-4 began on Day 25.
- the Vehicle was dosed intraperitoneally every 12 hours for 3 days (Days 25-27).
- GMI-1271 and GMI-1359 were dosed intraperitoneally at 40 mg/kg every 12 hours for 3 days (Days 25-27).
- G-CSF was dosed at 0.125 mg/kg subcutaneously every 12 hours for 3 days (Days 25-27).
- a “Nonimmune” group 5 was populated with age-matched, naive non-tumor bearing mice.
- mice in groups 1-5 were euthanized for blood and bone marrow collection.
- Flow cytometric analysis was used to determine CD62L and CD44 expression on CD8+ T cells in whole blood and bone marrow samples. Secondary analysis included AH-1 Dextramer analysis on the three tissue types and IFN ⁇ production in pooled blood and bone marrow samples. Samples were acquired using a 4 laser, 14 color Attune NxT Flow Cytometer with autosampler. CD62L and CD44 events were gated on CDS+ T cells.
- FIGS. 1 A- 1 C The distribution of CD8+ T cells in CT26 immune mice following administration of GMI-1271, GMI-1359, or G-CSF was analyzed. As shown in FIGS. 1 A- 1 C , the phenotypes of CD8+ T cells were determined in the peripheral blood and bone marrow samples. The data shows that, in contrast to G-CSF, treatment with GMI-1271 and GMI-1359 mobilized both na ⁇ ve ( FIG. 1 A ) and central memory (CM) CD8+ T cells ( FIG. 1 B ) into the peripheral blood. Redistribution of effector memory (EM) CD8+ T cells was not effected by GMI-1271 or GMI-1359 ( FIG. 1 C ).
- EM effector memory
- the percent of CD8+ lymphocytes in bone marrow armed to produce IFN ⁇ in the test subjects was also tested.
- the functional activity of the CD8+ MILs was assessed by IFN ⁇ production following in vitro stimulation with irradiated CT-26 tumor cells, the immunodominant CT-26 tumor antigen (AH1), or saline (unstimulated).
- MILs from tumor immunized mice treated with saline, GMI-1271, and GMI-1359 were primed to respond to both AH1 and whole tumor cells. Unstimulated MILs from tumor immune mice or stimulated CD8+ T-cells from non-immune mice did not produce IFN ⁇ .
- FIG. 3 illustrates that the percentage of CD8+ T-cells in peripheral blood primed to produce IFN ⁇ was markedly increased following treatment with GMI-1271 or GM1-1359 but not saline or G-CSF. Without being bound to theory, applicant understands that these results are likely due to a redistribution of tumor-primed MILs into the blood compartment.
- E-selectin antagonists such as GMI-1271 (a compound of formula (I)) and GMI-1359 (a compound of formula (II)).
- the administration of E-selectin antagonists results in mobilization or redistribution of tumor-primed MILs into peripheral blood.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer. Methods for treating or preventing cancers using MILs mobilized by E-selectin antagonists are further disclosed.
Description
- This application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/592,686, filed Nov. 30, 2017, which is incorporated by reference herein in its entirety.
- The present disclosure relates to methods for mobilizing tumor-specific, primed, marrow infiltrating lymphocytes (MILs) from the bone marrow using at least one E-selectin antagonist or compositions comprising the same as well as methods of treatment or prevention of cancers using the mobilized MILs.
- Immunotherapy has become a major focus of research in oncology. For example, for many years, Adoptive T-cell Therapy (ACT) has been used as a treatment for various cancers. ACT involves the isolation and ex vivo expansion of tumor specific T-cells to achieve greater number of T-cells than what could be obtained by vaccination alone. The tumor specific T-cells are then infused into patients with cancer in an attempt to give their immune system the ability to overwhelm remaining tumor via T-cells which can attack and kill cancer. Therefore, efficacious ACT requires the ability to activate tumor-specific T-cells that have the ability to travel to the tumor site and effectively kill their target. See, e.g., Noonan et al., Adoptive Transfer of Activated Marrow-Infiltrating Lymphocytes Induces Measureable Antitumor Immunity in the Bone Marrow in Multiple Myeloma, Cancer, Vol. 7, Issue 288 (May 15, 2015).
- Prominent in oncology research is the tumor microenvironment and the interaction of T-cells. T-cells that are able to effectively identify and/or attack cancer cells are of particular interest because, for example, they can allow the body to quickly mount a response to cancer. T-cells that have long life spans are also of particular interest because, for example, they will be able to provide the body with longer-lasting defenses. One promising type of T-cell are MILs. MILs are T-cells that have been primed to tumor antigens. MILs have been found in patients suffering from hematological malignancies and in metastatic disease arising from solid tumors such as prostate, breast, and lung cancers. The presence of tumor-specific T-cells in the bone marrow of patients with hematologic malignancies and solid tumors opens up the prospect of utilizing MILs for many therapies including adoptive T-cell therapy (ACT).
- A study by Noonan et al. has previously shown that anti-CD3/anti-CD28 ex vivo activated MILs have several fundamental properties, making them good candidates for cancer treatments. Noonan et al. at 2. Noonan found that, upon activation, MILs demonstrate significant tumor specificity compared to peripheral blood lymphocytes, target a broad range of antigens present on both the mature multiple myeloma plasma cells and their clonogenic precursors, and effectively kill multiple myeloma plasma cells. Id. Therefore, MILs exemplify a promising tumor-specific approach for treating cancers and cancerous malignancies.
- Accordingly, there is an unmet need for methods of mobilizing MILs and inducing them to leave the marrow, where they can, for example, be used in ex vivo manipulations such as the development of CAR T-cells or used in autologous or allogenic donation.
- Additionally, although ACT provides one option for cancer treatments, it requires ex vivo expansion of the cells, which can be time-consuming, inconvenient to patients, and labor intensive.
- Accordingly, there is an unmet need for methods of mobilizing MILs for in vivo treatments.
-
FIG. 1A is an exemplary graph of the percentage of CD8+ lymphocytes in the population of CD62L+CD44− (naïve) lymphocytes found in bone marrow and peripheral blood samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, granulocyte-colony stimulating factor (G-CSF), or saline. -
FIG. 1B is an exemplary graph of the percentage of CD8+ lymphocytes in the population of CD62L+CD44+ (central memory or CM) lymphocytes found in bone marrow and peripheral blood samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, G-CSF, or saline. -
FIG. 1C is an exemplary graph of the percentage of CD8+ lymphocytes in the population of CD62L-CD44+(effector memory or EM) lymphocytes found in bone marrow and peripheral blood samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, G-CSF, or saline. -
FIG. 2 is an exemplary graph of the percentage of IFN+ lymphocytes in the population of CD8+ lymphocytes from bone marrow samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, G-CSF, or saline. -
FIG. 3 is an exemplary graph of the percentage of IFN+ lymphocytes in the population of CD8+ lymphocytes from peripheral blood samples taken from CT26 non-immune mice acting as controls and in CT26 immune mice following administration of GMI-1271, GMI-1359, G-CSF, or saline. - The terms defined below are more fully defined by reference to the specification as a whole. While the terms used herein are believed to be well understood by one of ordinary skill in the art, the definitions included in this document are set forth to facilitate explanation of the presently-disclosed subject matter.
- Following long-standing patent law convention, the terms “a,” “an,” and “the” refer to “one or more” when used in this application, including the claims. Thus, for example, reference to “a cell” includes one cell or a plurality of cells, and so forth.
- Throughout this disclosure, various embodiments can be presented in a range format. Numeric ranges are inclusive of the numbers defining the range. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range, such as from 1 to 6, should be considered to have specifically disclosed subranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3.8, 4, 5.1, 5.3, and 6. This applies regardless of the breadth of the range.
- E-selectin (CD62E) is a cell adhesion molecule that is expressed on activated endothelial cells and plays an important role in leukocyte recruitment to the site of injury. The terms “E-selectin antagonist” means an agent that inhibits an activity of E-selectin or inhibits the binding of E-selectin to one or more E-selectin ligands (which in turn may inhibit a biological activity of E-selectin). The term “E-selectin antagonist” includes antagonists of E-selectin only, as well as antagonists of E-selectin and either P-selectin or L-selectin, and antagonists of E-selectin, P-selectin, and L-selectin. E-selectin antagonists include the glycomimetic compounds described herein that inhibit interaction of E-selectin with sialyl Lea (sLea) or sialyl Lex (sLex). E-selectin antagonists also include antibodies, polypeptides, peptides, peptidomimetics, and aptamers which bind at or near the binding site on E-selectin to inhibit E-selectin interaction with sialyl Lea (sLea) or sialyl Lex (sLex)).
- The term “non-glycomimetic moiety” includes moieties having a structure not intended to mimic a carbohydrate molecule. A non-glycomimetic moiety may not be (and is typically not) active as an E-selectin antagonist. Instead, non-glycomimetic moieties are generally moieties added to a glycomimetic moiety for purposes of altering at least one property, such as solubility, bio-availability, lipophilicity and/or other drug-like properties of the glycomimetic.
- The terms “patient,” “subject,” “individual,” and the like are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein. In certain non-limiting embodiments, the patient, subject or individual is a human.
- The term “therapy” refers to “treating” or “treatment” of a disease or condition including inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease). “Therapy” may also refer to prophylactic treatment, which includes preventing or delaying the onset of the disease or condition from occurring in a subject that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease.
- The term “treatment” means the slowing down, interruption, arrest, reversal, or stoppage of the progression of the disease, which does not necessarily require the complete elimination of all the signs and symptoms of the disease. “Treatment” also includes prophylactic treatment to prevent or delay the onset of the disease or condition from occurring in a subject that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease. “Treatment” further means preventing or delaying the relapse or recurrence of the disease or condition in a subject that is considered in remission for the disease or condition. Furthermore, it is not necessary for the treatment to show effectiveness in 100% of the patients treated, rather, the term “treatment” is intended to mean that a statistically significant proportion of patients can be treated effectively, in such a way that the symptoms and clinical signs show at least an improvement. The person skilled in the art can easily establish whether the proportion is statistically significant using various statistical methods (e.g. confidence intervals, determination of them p value, Student's t-test, Mann-Whitney test etc.). Confidence intervals have a confidence of at least 90%, at least 95%, at least 97%, at least 98% or at least 99%. The p values are 0.1, 0.05, 0.01, 0.005 or 0.0001.
- The term “prevention of relapse” refers to the reduction of the risk of the return of a disease or condition and/or extending the time until a relapse occurs.
- As used herein, “together” is used to mean that the agents are administered concurrently. They can be administered in the same composition or in separate compositions. In contrast to “together,” “sequentially” is used herein to mean that the gap between administering one agent and the other is significant, i.e., the first administered agent may no longer be present in the bloodstream in a therapeutic amount when the second agent and/or third agent is administered. When administered sequentially, the compounds may be administered in any order.
- Briefly, provided herein are agents that are E-selectin antagonists, compositions comprising the agents, and methods for using the agents for mobilizing marrow infiltrating lymphocytes from the bone marrow. Glycomimetic compounds that may be used in these methods are E-selectin antagonists as described herein. Additionally, compounds disclosed herein may be heterobifunctional, for example, an E-selectin antagonist linked to a CXCR4 chemokine receptor antagonist.
- E-selectin is an adhesion molecule expressed on endothelial cells and binds to specific carbohydrate sequences (sialyl Lex and sialyl Lea) found on the surfaces of opposing bound cells. The endothelium in most of the normal vasculature does not express E-selectin until stimulation of protein synthesis by inflammatory mediators. After about three hours of de novo protein synthesis, E-selectin is then expressed as a result of an inflammatory response. In contrast, E-selectin is constitutively expressed in the bone marrow by the endothelial cells lining the blood vessels. Here, it is thought, without wishing to be bound by theory, that MILs reside in the vasculature niche of the bone marrow by binding to adhesion molecules, including E-selectin. In this disclosure, antagonists of E-selectin are provided that mobilize MILs from the bone marrow. Such antagonists may include but are not limited to small molecules, antibodies, aptamers, peptides, and glycoproteins. MILs derived from mobilized cells from the bone marrow have a wide range of therapeutic uses. For example, MILs can be induced to leave the marrow and distribute to the periphery where they may act in vivo or where they can be collected for ex vivo manipulation such as engineering CAR T-cells.
- Furthermore, it is known that some individuals do not respond well to the use of Plerixafor (AMD-3100) and/or G-CSF due to age, disease, and certain genetic conditions. Thus, to the extent those prior art methods are found to be ineffective in mobilizing MILs, the disclosed methods provide an alternative.
- In some embodiments, a method is provided for mobilizing MILs by inhibiting E-selectin, a major adhesion protein in the bone marrow vasculature. This method may comprise using the at least one E-selectin antagonist alone or in combination with other agents used to mobilize hematopoietic stem cells. Specific small molecule antagonists of E-selectin that mobilize hematopoietic cells and which are therefore useful for these methods and other methods are described herein.
- In some embodiments, at least one E-selectin antagonist is administered to a patient. In some embodiments, at least one E-selectin antagonist is administered to a cancer patient in remission. In some embodiments, at least one E-selectin antagonist is administered as a cancer vaccine to stimulate MILs in a cancer patient or cancer survivor to prevent relapse.
- In some embodiments, a method of treating cancer and/or preventing a cancer relapse is provided comprising administering to a patient at least one E-selectin antagonist in an amount sufficient to mobilize MILs of the patient into the peripheral blood.
- In some embodiments, a method of treating cancer and/or preventing a cancer relapse is provided comprising administering to a donor patient at least one E-selectin antagonist in an amount of sufficient to mobilize MILs of the patient out of the marrow (e.g., into the peripheral blood), recovering MILS (e.g., recovering them from the peripheral blood), and transplanting at least a portion of the MIL cell population to the donor patient or another patient. In some embodiments, the MIL cell population is expanded ex vivo before transplantation.
- In some embodiments, a method of preventing cancer is provided comprising administering to a donor patient at least one E-selectin antagonist in an amount sufficient to mobilize MILs of the patient out of the bone marrow (e.g., into the peripheral blood), recovering MILs (e.g., recovering them from the peripheral blood), and transplanting at least a portion of MIL cell population to a subject (e.g., a non-cancer patient, a patient suffering from a different form or type of cancer than the donor patient, etc.). In some embodiments, the MIL cell population is expanded ex vivo before transplantation.
- In some embodiments, the at least one E-selectin antagonist is in the form of a pharmaceutical composition. In some embodiments the pharmaceutical composition further comprises at least one pharmaceutically acceptable ingredient.
- At least one E-selectin antagonist may be chosen from glycomimetics. In some embodiments, at least one E-selectin antagonist is chosen from sialyl Lewisx (sLex) and sLex mimetics. In some embodiments, at least one E-selectin antagonist is chosen from glycomimetic antagonists of E-selectin, antibodies directed to E-selectin, aptamers to E-selectin, peptides or polypeptides directed to E-selectin, and peptidomimetics directed to E-selectin.
- In some embodiments, a colony stimulating factor is administered with at least one E-selectin antagonist to the cancer patient.
- In some embodiments, the cancer patient has received or will receive chemotherapy and/or radiotherapy. In some embodiments, the chemotherapy comprises administration of bortexomib and/or gemcitabine. In some embodiments, the cancer is a hematologic cancer. In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is a liquid cancer.
- In some embodiments, the patient has been diagnosed with a first type of cancer and the cancer for which the method is performed to treat or prevent is a second type of cancer.
- In some embodiments, a composition comprising MILs mobilized out of the bone marrow by at least one E-selectin antagonist is disclosed.
- In some embodiments, treatment of cancer is provided by the mobilization of MILs following the administration of at least one E-selectin antagonist (i.e., in vivo mobilization of MILs). In some embodiments, relapse of cancer is prevented by the mobilization of MILs following the administration of at least one E-selectin antagonist.
- In some embodiments, at least one E-selectin antagonist is chosen from compounds of Formula (I):
- isomers of Formula (I), tautomers of Formula (I), and pharmaceutically acceptable salts of any of the foregoing, wherein:
-
- R1 is chosen from C1-C8alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, and C2-C8 haloalkynyl groups;
- R2 is chosen from H, -M, and -L-M;
- R3 is chosen from —OH, —NH2, —OC(═O)Y1, —NHC(═O)Y1, and —NHC(═O)NHY1 groups, wherein Y1 is chosen from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C18 aryl, and C1-C13 heteroaryl groups;
- R4 is chosen from —OH and —NZ1Z2 groups, wherein Z1 and Z2, which may be identical or different, are each independently chosen from H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, and C2-C8 haloalkynyl groups, wherein Z1 and Z2 may together form a ring;
- R5 is chosen from C3-C8 cycloalkyl groups;
- R6 is chosen from —OH, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, and C2-C8 haloalkynyl groups;
- R7 is chosen from —CH2OH, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, and C2-C8 haloalkynyl groups;
- R8 is chosen from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, and C2-C8 haloalkynyl groups;
- L is chosen from linker groups; and
- M is a non-glycomimetic moiety chosen from —C(═O)NH(CH2)1-4NH2, C1-C8 alkyl, —C(═O)OY2, and moieties comprising polyethylene glycol, thiazolyl, or chromenyl, wherein Y2 is chosen from C1-C4 alkyl, C2-C4 alkenyl, and C2-C4 alkynyl groups.
- In some embodiments, at least one E-selectin antagonist is chosen from compounds of Formula (I), wherein M is a non-glycomimetic moiety comprising polyethylene glycol, thiazolyl, or chromenyl. In some embodiments, at least one E-selectin antagonist is chosen from compounds of Formula (I), wherein M is a non-glycomimetic moiety comprising polyethylene glycol.
- As would be recognized by one of ordinary skill in the art, the phrase “isomers of Formula (I), tautomers of Formula (I), and pharmaceutically acceptable salts of any of the foregoing” includes hydrates and solvates.
- In some embodiments, at least one E-selectin antagonist is chosen from compounds of Formula (I), wherein the non-glycomimetic moiety comprises polyethylene glycol.
- In some embodiments, at least one E-selectin antagonist is chosen from compounds of Formula (II):
- isomers of Formula (II), tautomers of Formula (II), and pharmaceutically acceptable salts of any of the foregoing, wherein:
-
- R1 is chosen from H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, and C2-C8 haloalkynyl groups;
- R2 is chosen from —OH, —NH2, —OC(═O)Y1, —NHC(═O)Y1, and —NHC(═O)NHY1 groups, wherein Y1 is chosen from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C18 aryl, and C1-C13 heteroaryl groups;
- R3 is chosen from —CN, —CH2CN, and —C(═O)Y2 groups, wherein Y2 is chosen from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, —OZ1, —NHOH, —NHOCH3, —NHCN, and —NZ1Z2 groups, wherein Z1 and Z2, which may be identical or different, are independently chosen from H, C1-C8alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, and C2-C8 haloalkynyl groups, wherein Z1 and Z2 may together form a ring;
- R4 is chosen from C3-C8 cycloalkyl groups;
- R5 is independently chosen from H, halo, Ci-Ce alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, and C2-C8 haloalkynyl groups;
- n is chosen from integers ranging from 1 to 4; and
- L is chosen from linker groups.
- As would be recognized by one of ordinary skill in the art, the phrase “isomers of Formula (II), tautomers of Formula (II), and pharmaceutically acceptable salts of any of the foregoing” includes hydrates and solvates.
- In some embodiments, at least one E-selectin antagonist is chosen from compounds of Formula (IIa):
- In some embodiments, the linker groups of Formula I and/or Formula II are independently chosen from groups comprising spacer groups, such spacer groups as, for example, —(CH2)p— and —O(CH2)p—, wherein p is chosen from integers ranging from 1 to 30. In some embodiments, p is chosen from integers ranging from 1 to 20. Other non-limiting examples of spacer groups include carbonyl groups and carbonyl-containing groups such as, for example, amide groups. A non-limiting example of a spacer group is
- In some embodiments, the linker groups are independently chosen from
- Other linker groups, such as, for example, polyethylene glycols (PEGs) and —C(═O)—NH—(CH2)p—C(═O)—NH—, wherein p is chosen from integers ranging from 1 to 30, or wherein p is chosen from integers ranging from 1 to 20, will be familiar to those of ordinary skill in the art and/or those in possession of the present disclosure.
- In some embodiments, at least one linker group is
- In some embodiments, at least one linker group is
- In some embodiments, at least one linker group is chosen from —C(═O)NH(CH2)2NH—, —CH2NHCH2—, and —C(═O)NHCH2—. In some embodiments, at least one linker group is —C(═O)NH(CH2)2NH—.
- In some embodiments, at least one E-selectin antagonist is chosen from compounds of Formula (Ia):
- wherein n is chosen from integers ranging from 1 to 100. In some embodiments, n is chosen from 4, 8, 12, 16, 20, 24, and 28.
- In some embodiments, at least one E-selectin antagonist is chosen from E-selectin antagonists disclosed in U.S. Pat. No. 9,109,002, which is hereby incorporated by reference. In some embodiments, at least one E-selectin antagonist is GMI-1271. See, e.g., Price et al., “Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone,” Science Translational Medicine, Vol. 8(340), May 25, 2016, [DOI:10.1126/scitranslmed.aad4059]; Dutta et al., “E-Selectin Inhibition Mitigates Splenic HSC Activation and Myelopoiesis in Hypercholesterolemic Mice With Myocardial Infarction”, Arterioscler Thromb Vasc Biol [DOI: 10.1161/ATVBAHA.116.307519]
- In some embodiments, at least one E-selectin antagonist is chosen from compounds of the following Formulae:
- In some embodiments, at least one E-selectin antagonist is chosen from compounds of the following Formulae:
- In some embodiments, at least one E-selectin antagonist is chosen from E-selectin antagonists disclosed in U.S. Pat. No. 8,410,066 and PCT/US2015/063191, which are hereby incorporated by reference. In some embodiments, at least one E-selectin antagonist is GMI-1359. See, e.g., Steele, Maria M. et al., “A small molecule glycomimetic antagonist of E-selectin and CXCR4 (GMI-1359) prevents pancreatic tumor metastasis and improves chemotherapy [abstract],” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015 Apr. 18-22, Philadelphia, PA; Philadelphia (PA): AACR, Cancer Res 2015, 75(15 Suppl):Abstract nr 425. doi:10.1158/1538-7445.AM2015-425; Gravina, Giovanni L. et al., “Dual E-selectin and CXCR4 inhibition reduces tumor growth and increases the sensitivity to docetaxel in experimental bone metastases of prostate cancer [abstract],” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015 Apr. 18-22, Philadelphia, PA; Philadelphia (PA): AACR, Cancer Res 2015, 75(15 Suppl):Abstract nr 428. doi:10.1158/1538-7445.AM2015-428, all of which are incorporated by reference.
- Synthesis of the compounds of formula II (and substructures, and specific compounds) may be performed as described in U.S. Publication No. US 2017/0305951, which is incorporated herein by reference.
- Also provided are pharmaceutical compositions comprising at least one compound of formula (I) and/or formula (II). Such pharmaceutical compositions are described in greater detail herein. These compounds and compositions may be used in the methods described herein.
- In some embodiments, at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) and/or a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) may be used in methods for releasing MILs out of bone marrow and into circulating blood and enhancing retention of MILs in the blood.
- In some embodiments, at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) and/or a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) may be used in methods described herein for treatment and/or prevention of a cancer. The cancer may be a cancer in which the cancer cells may leave the primary site. A primary site may be, for example, solid tissue (e.g., breast, prostate, or pancreatic) or the bloodstream.
- One use of the method is, for example, for MILs harvesting. MILs may be needed, for example, after high-dose chemotherapy treatment. A compound described herein may be used, for example, to release MILs into circulating blood and enhance retention of MILs in the blood. The method may include a further step of collecting MILs that are released. A variety of techniques are known in the art for collecting MILs that have been released into the blood. For example, apheresis may be utilized.
- The release of MILs from bone marrow into circulating blood and retention therein has a variety of uses. For example, the mobilized MILs may be collected from the blood. A use of such collected cells is to obtain healthy MILs from an individual prior to treatment of the individual in a manner such that MILs are suppressed. Following treatment, the individual can receive a transplantation utilizing MILs collected prior to treatment. This is useful, for example, where an individual needs to be subjected to a chemotherapy protocol that may damage MILs.
- It can be desirable to additionally treat an individual with at least one (i.e., one or more) colony stimulating factor. Such a factor may be administered, for example, before or simultaneous with administration of at least one of the above-described compounds. Where administration is simultaneous, the combination may be administered from a single container or two (or more) separate containers. An example of a suitable colony stimulating factor is G-CSF. G-CSF induces the bone marrow to grow and produce more stem cells. A compound described herein aids in releasing MILs into circulating blood. MILs produced in bone marrow and released into circulating blood, as a result of the combination of the administration (separately or together) of a compound described herein and G-CSF, may be collected as described above. Such collected MILs may be, for example, administered to the individual after chemotherapy. Application of a compound described herein to mobilization and harvesting of healthy MILs from bone marrow treated with G-CSF provides cells useful, for example, for transplantation.
- In some embodiments, at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) and/or a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) may be used in methods described herein for treatment and/or prevention of tumor metastasis. In some embodiments, at least one additional chemotherapy agent such as gemcitabine is administered to the individual.
- In some embodiments, at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) and/or a pharmaceutical composition comprising at least one compound of E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) may be used in methods for treatment and/or prevention of an inflammatory disease in which the adhesion or migration of cells occurs in the disease.
- Examples of inflammatory diseases include inflammatory skin disorders such as atopic dermatitis and psoriasis. The treatment may reduce (partially or totally) the disease or a complication associated therewith, such as pain. The treatment may be used in conjunction with one or more other therapies for such an inflammatory disease or a complication associated therewith.
- In some embodiments, at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) and/or a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) may be used for treating at least one of the diseases, disorders, and conditions described herein or for the preparation or manufacture of a medicament for use in treating at least one of the diseases, disorders, and/or conditions described herein. Each of these methods and uses is described in greater detail.
- In certain embodiments, the methods and E-selectin antagonists described herein are therefore useful for treating hematologic malignancies and metastatic disease, particularly in combination or as an adjunct therapy with chemotherapy and/or radiation therapy.
- In some embodiments, at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) and/or a pharmaceutical composition comprising at least one E-selectin antagonist (e.g., a compound of formula (I) or formula (II)) may be used in combination with one or more other agents that mobilize hematopoietic cells. Such agents include, for example, G-CSF; AMD-3100 or other CXCR4 antagonists; GRO-β (CXCL2) and an N-terminal 4-amino truncated form (SB-251353); IL-8SDF-1a peptide analogs, CTCE-0021 and CTCE-0214; and the SDF1 analog, Met-SDF-1β (see, e.g., Pelus, supra and references cited therein). The appropriate therapeutic regimen for administering at least one E-selectin antagonist in combination with another mobilizing agent or agents can be readily determined by a person skilled in the clinical art.
- In particular embodiments of the methods described herein, the subject is a human or non-human animal. A subject in need of the treatments described herein may exhibit symptoms or sequelae of cancer disease, disorder, or condition described herein or may be at risk of developing the disease, disorder, or condition. Non-human animals that may be treated include mammals, for example, non-human primates (e.g., monkey, chimpanzee, gorilla, and the like), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, swine (e.g., pig, miniature pig), equine, canine, feline, bovine, and other domestic, farm, and zoo animals.
- The effectiveness of a compound, agent, or composition described herein in treating or preventing a disease or disorder or condition, and determining and adjusting an appropriate dosing regimen (e.g., adjusting the amount of compound per dose and/or number of doses and frequency of dosing), can readily be determined by a person of ordinary skill in the medical and clinical arts. One or any combination of diagnostic methods, including physical examination, assessment and monitoring of clinical symptoms, and performance of analytical tests and methods described herein, may be used for monitoring the health status of the subject.
- Mobilization of MILs can be monitored using methods and techniques routinely practiced in the art the skilled person. MILs may be identified by identifying the presence or absence of certain cell surface markers. For example, the presence and level of MILs can be determined by methods that detect the presence of CD8 or CD4 on the surface of cells (i.e., CD8+ or CD4+ cells).
- The compounds described herein may be formulated in a pharmaceutical composition for use in medicaments and therapeutics for mobilizing MILs and for treatment or preventive (or prophylactic) treatment (e.g., reducing the likelihood of occurrence or of exacerbation of a disease, or of one or more symptoms of the disease) of a disease or disorder for which mobilizing MILs is beneficial or for which receiving a MILs transplant or replacement is beneficial. The methods and excipients described herein are exemplary and are in no way limiting.
- The dose of an E-selectin antagonist described herein may depend upon the subject's condition, that is, stage of the disease, severity of symptoms caused by the disease, general health status, as well as age, gender, and weight, and other factors apparent to a person of ordinary skill in the medical art. Similarly, the dose of the therapeutic for treating a disease or disorder may be determined according to parameters understood by a person of ordinary skill in the medical art.
- Pharmaceutical compositions may be administered in a manner appropriate to the disease or disorder to be treated as determined by persons of ordinary skill in the medical arts. An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as discussed herein, including the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose (or effective dose) and treatment regimen provides the pharmaceutical composition(s) as described herein in an amount sufficient to provide therapeutic and/or prophylactic benefit (for example, an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity or other benefit as described in detail above).
- The pharmaceutical compositions described herein may be administered to a subject in need thereof by any one of several routes that effectively deliver an effective amount of the compound. Such administrative routes include, for example, topical, oral, nasal, intrathecal, enteral, buccal, sublingual, transdermal, rectal, vaginal, intraocular, subconjunctival, sublingual or parenteral administration, including subcutaneous, intravenous, intramuscular, intrasternal, intracavernous, intrameatal or intraurethral injection or infusion. Compositions administered by these routes of administration and others are described in greater detail herein.
- A pharmaceutical composition may be a sterile aqueous or sterile non-aqueous solution, suspension or emulsion, which additionally comprises a physiologically acceptable excipient (pharmaceutically acceptable or suitable excipient or carrier) (i.e., a non-toxic material that does not interfere with the activity of the active ingredient). Such compositions may be in the form of a solid, liquid, or gas (aerosol). Alternatively, compositions described herein may be formulated as a lyophilizate, or compounds and polypeptides or peptides described herein may be encapsulated within liposomes using technology known in the art. Pharmaceutical compositions may also contain other components, which may be biologically active or inactive. Such components include, but are not limited to, buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione, stabilizers, dyes, flavoring agents, and suspending agents and/or preservatives.
- Any suitable excipient or carrier known to those of ordinary skill in the art for use in pharmaceutical compositions may be employed in the compositions described herein. Excipients for therapeutic use are well known, and are described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)). In general, the type of excipient is selected based on the mode of administration, as well as the chemical composition of the active ingredient(s). Pharmaceutical compositions may be formulated for any appropriate manner of administration, including, for example, topical, oral, nasal, intrathecal, enteral, buccal, sublingual, transdermal, rectal, vaginal, intraocular, subconjunctival, sublingual or parenteral administration, including subcutaneous, intravenous, intramuscular, intrasternal, intracavernous, intrameatal or intraurethral injection or infusion. For parenteral administration, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above excipients or a solid excipient or carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, kaolin, glycerin, starch dextrins, sodium alginate, carboxymethylcellulose, ethyl cellulose, glucose, sucrose and/or magnesium carbonate, may be employed.
- A pharmaceutical composition (e.g., for oral administration or delivery by injection) may be in the form of a liquid. A liquid pharmaceutical composition may include, for example, one or more of the following: a sterile diluent such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils that may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents; antioxidants; chelating agents; buffers and agents for the adjustment of tonicity such as sodium chloride or dextrose. A parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. The use of physiological saline is preferred, and an injectable pharmaceutical composition is preferably sterile.
- For oral formulations, at least one E-selectin antagonist described herein can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with any one or more conventional additives, disintegrators, lubricants, and if desired, diluents, buffering agents, moistening agents, preservatives, coloring agents, and flavoring agents. The compositions may be formulated to include a buffering agent to provide for protection of the active ingredient from low pH of the gastric environment and/or an enteric coating. A composition may be formulated for oral delivery with a flavoring agent, e.g., in a liquid, solid or semi-solid formulation and/or with an enteric coating.
- Oral formulations may be provided as gelatin capsules, which may contain the active compound or biological along with powdered carriers. Similar carriers and diluents may be used to make compressed tablets. Tablets and capsules can be manufactured as sustained release products to provide for continuous release of active ingredients over a period of time. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
- A pharmaceutical composition may be formulated for sustained or slow release. Such compositions may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain the active therapeutic dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane. Excipients for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. The amount of active therapeutic contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release, and the nature of the condition to be treated or prevented.
- The pharmaceutical compositions described herein can be formulated as suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases. The pharmaceutical compositions may be prepared as aerosol formulations to be administered via inhalation. The compositions may be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen and the like.
- The at least one E-selectin antagonist may be administered topically (e.g., by transdermal administration). Topical formulations may be in the form of a transdermal patch, ointment, paste, lotion, cream, gel, and the like. Topical formulations may include one or more of a penetrating agent or enhancer (also call permeation enhancer), thickener, diluent, emulsifier, dispersing aid, or binder. Physical penetration enhancers include, for example, electrophoretic techniques such as iontophoresis, use of ultrasound (or “phonophoresis”), and the like. Chemical penetration enhancers are agents administered either prior to, with, or immediately following administration of the therapeutic, which increase the permeability of the skin, particularly the stratum corneum, to provide for enhanced penetration of the drug through the skin. Additional chemical and physical penetration enhancers are described in, for example, Transdermal Delivery of Drugs, A. F. Kydonieus (ED) 1987 CRL Press; Percutaneous Penetration Enhancers, eds. Smith et al. (CRC Press, 1995); Lenneras et al., J. Pharm. Pharmacol. 54:499-508 (2002); Karande et al., Pharm. Res. 19:655-60 (2002); Vaddi et al., Int. J. Pharm. 91:1639-51 (2002); Ventura et al., J. Drug Target 9:379-93 (2001); Shokri et al., Int. J. Pharm. 228(1-2):99-107 (2001); Suzuki et al., Biol. Pharm. Bull. 24:698-700 (2001); Alberti et al., J. Control Release 71:319-27 (2001); Goldstein et al., Urology 57:301-5 (2001); Kiijavainen et al., Eur. J. Pharm. Sci. 10:97-102 (2000); and Tenjarla et al., Int. J. Pharm. 192:147-58 (1999).
- Routes of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, intrathecal, and subcutaneous routes. In some embodiments, the compounds or compositions are administered locally (i.e., near a cancer tumor). In some embodiments, one or more of the compounds or compositions are administered using different routes of administration.
- The compounds or pharmaceutical composition(s) can be administered in one or more doses and treatment regimens, which may be the same or different. In some embodiments, each of the compounds or pharmaceutical composition(s) is administered in an amount ranging from about 1 mg/kg to about 50 mg/kg once a day. In other embodiments, the dosage may be at any dosage including, but not limited to, about 1 μg/kg, 25 μg/kg, 50 μg/kg, 75 μg/kg, 100 μg/kg, 125 μg/kg, 150 μg/kg, 175 μg/kg, 200 μg/kg, 225 μg/kg, 250 μg/kg, 275 μg/kg, 300 μg/kg, 325 μg/kg, 350 μg/kg, 375 μg/kg, 400 μg/kg, 425 μg/kg, 450 μg/kg, 475 μg/kg, 500 μg/kg, 525 μg/kg, 550 μg/kg, 575 μg/kg, 600 μg/kg, 625 μg/kg, 650 μg/kg, 675 μg/kg, 700 μg/kg, 725 μg/kg, 750 μg/kg, 775 μg/kg, 800 μg/kg, 825 μg/kg, 850 μg/kg, 875 μg/kg, 900 μg/kg, 925 μg/kg, 950 μg/kg, 975 μg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, or 10 mg/kg.
- In some embodiments, the compounds or pharmaceutical composition(s) are administered in any of these amounts and ranges once a day, more than once a day, every other day, every two days, etc. One of more treatment cycles may be repeated, and any number of cycles is contemplated. The number of treatments per day and the amount per dose for each compound or pharmaceutical composition may vary during each cycle.
- Kits with unit doses of one or more of the compounds, polypeptides, peptides, aptamers, antibodies and antigen binding fragments thereof described herein, usually in oral or injectable doses, are provided. Such kits may include a container containing the unit dose, an informational package insert describing the use and attendant benefits of the therapeutic in treating the pathological condition of interest, and optionally an appliance or device for delivery of the composition.
- The following examples provide illustrative embodiments of the invention. One of ordinary skill in the art will recognize the numerous modifications and variations that may be performed without altering the spirit or scope of the present invention. Such modifications and variations are encompassed within the scope of the invention. The Examples do not in any way limit the invention.
- In the disclosed examples, the following materials and methods were used.
- Chemicals: GMI-1271 (100% parent, >97% purity) was obtained as a white, crystalline substance. It was stored protected from light at −20° C. The compound was formulated in sterile phosphate buffered saline (PBS), resulting in a clear, colorless solution with a pH value of 7.4 and a concentration of 4 mg/mL. The dosing solution was prepared 12 hours prior to the first dose and stored at 4° C. protected from light between treatments.
- GMI-1359 (100% parent, >97% purity) was obtained as a white, granular powder. It was stored protected from light at −20° C. The compound was formulated in sterile (PBS), resulting in a clear, colorless solution with a pH value of 9.2 and a concentration of 4 mg/mL. The dosing solution was prepared 12 hours prior to the first dose and stored at 4° C. protected from light between treatments.
- G-CSF (0.3 mg/mL) was obtained as a clear, colorless stock solution. It was stored protected from light and at 4° C. The dosing solution was prepared by diluting the stock solution with 5% dextrose. The result was a clear, colorless solution with a pH value of 4.8 and a concentration of 0.0128 mg/mL. The dosing formulation was prepared daily and was stored at room temperature and protected from light, between treatments.
- Anti-CTLA-4 (7.36 mg/mL) was obtained as a clear, colorless stock solution. It was stored protected from light and at 4° C. The dosing solution was prepared by diluting the stock solution with PBS. The result was a clear, colorless solution with a pH value of 7 and a concentration of 1 mg/mL. The dosing formulation was prepared fresh weekly and stored at 4° C. and protected from light between treatments.
- Animals and Husbandry: Female Envigo Balb/c mice (BALB/cAnNHsd) were used in this study. They were 6-7 weeks old on Day 1 of the experiment. The animals were fed irradiated Harlan 2918.15 Rodent Diet and water ad libitum. Animals were housed in Innovive disposable ventilated caging with corn cob bedding inside Biobubble® Clean Rooms that provide H.E.P.A filtered air into the bubble environment at 100 complete air changes per hour. All treatments, body weight determinations, and tumor measurements were carried out in the bubble environment. The environment was controlled to a temperature range of 70°±2° F. and a humidity range of 30-70%.
- Cancer Cell Preparation: CT26WT cells were obtained. They were grown in RPMI 1640 medium which was modified with 1% 100 mM Na pyruvate, 1% 1 M HEPES buffer, 1% of a 45% glucose solution and supplemented with 10% non-heat-inactivated Fetal Bovine Serum (FBS) and 1% 100× Penicillin/Streptomycin/L-Glutamine (PSG). The growth environment was maintained in an incubator with a 5% CO2 atmosphere at 37° C. When expansion was complete, the cells (passage 3) were trypsinized using 0.25% trypsin-EDTA solution following cell detachment, the trypsin was inactivated by dilution with complete growth medium and any clumps of cells were separated by pipetting. The cells were centrifuged at 200 rcf for 8 minutes at 4° C., the supernatant was aspirated, and the pellet was re-suspended in cold Dulbecco's Phosphate Buffered Saline (DPBS) by pipetting. An aliquot of the homogeneous cell suspension was diluted in a trypan blue solution and counted using a Luna automated cell counter. The pre-implantation cell viability was 93%. The cell suspension was centrifuged at 200 rcf for 8 minutes at 4° C. The supernatant was aspirated and the cell pellet was re-suspended in cold serum-free medium to generate a final concentration of 2.50E+06 trypan-excluding cells/mL. The cell suspension was maintained on wet ice during implantation.
- Following implantation, an aliquot of the remaining cells was diluted with a trypan blue solution and counted to determine the post-implantation cell viability (92%).
- Test animals in were implanted subcutaneously, high in the axilla (just under the fore limb) on
Day 0 with 5.0E+05 cells in 0.2 mL of serum-free medium using a 27-gauge needle and syringe. - Protocol for Detection and Mobilization of MILs in the CT-26 tumor model: GMI-1271 is a potent, small-molecule, glycomimetic antagonist of E-selectin. GMI-1359 is a potent, small-molecule glycomimetic dual antagonist, targeting E-selectin and CXCR4. The effects of inhibiting either E-selectin with GMI-1271 or E-selectin and CXCR4 with GMI-1359 on MIL mobilization was tested in BALB/c mice that had been induced to reject the syngeneic CT26 colon carcinoma via anti-CTLA-4 T cell checkpoint antibody. The experimental protocol is summarized in Table 1.
-
TABLE 1 Parameters Group Treatment Regimen (12 hrs post final dose) Tumor immune, 10 ml/kg IP bid × PB & BM CD8+ phenotype saline 3d Tumor specific PB & BM Tumor immune, 40 mgkg−1 IP bid × in vitro responses: GMI-1271 3d defined as CD8+/ Tumor immune, 40 mgkg−1 IP bid × IFNγ+ following tumor GMI-1359 3d pulse Tumor immune, 0.125 mgkg−1SC bid × G-CSF 3d Non-immune, 10 ml/kg IP bid × saline 3d - Treatment with anti-CTLA-4 for all mice implanted with CT26.WT began on Day 3. All mice were dosed intraperitoneally on
Days 3, 6, 10, 13, and 17. All mice were dosed according to individual body weight on the day of treatment (0.2 mg/20 g). - On Day 25, mice without tumors following CTLA-4 treatment were distributed into the four “Tumor Immune” treatment groups indicated in Table 1 such that the mean body weight within each group was within 10% of the overall mean.
- Treatment for “Tumor Immune” groups 1-4 began on Day 25. The Vehicle was dosed intraperitoneally every 12 hours for 3 days (Days 25-27). GMI-1271 and GMI-1359 were dosed intraperitoneally at 40 mg/kg every 12 hours for 3 days (Days 25-27). G-CSF was dosed at 0.125 mg/kg subcutaneously every 12 hours for 3 days (Days 25-27).
- A “Nonimmune”
group 5 was populated with age-matched, naive non-tumor bearing mice. - At 12 hours after the final dose of test agents, all mice in groups 1-5 (treatment “Tumor Immune” groups 1-4 and control “Nonimmune” group 5) were euthanized for blood and bone marrow collection.
- Flow cytometric analysis was used to determine CD62L and CD44 expression on CD8+ T cells in whole blood and bone marrow samples. Secondary analysis included AH-1 Dextramer analysis on the three tissue types and IFNγ production in pooled blood and bone marrow samples. Samples were acquired using a 4 laser, 14 color Attune NxT Flow Cytometer with autosampler. CD62L and CD44 events were gated on CDS+ T cells.
- The distribution of CD8+ T cells in CT26 immune mice following administration of GMI-1271, GMI-1359, or G-CSF was analyzed. As shown in
FIGS. 1A-1C , the phenotypes of CD8+ T cells were determined in the peripheral blood and bone marrow samples. The data shows that, in contrast to G-CSF, treatment with GMI-1271 and GMI-1359 mobilized both naïve (FIG. 1A ) and central memory (CM) CD8+ T cells (FIG. 1B ) into the peripheral blood. Redistribution of effector memory (EM) CD8+ T cells was not effected by GMI-1271 or GMI-1359 (FIG. 1C ). - The percent of CD8+ lymphocytes in bone marrow armed to produce IFNγ in the test subjects was also tested. As shown in
FIG. 2 , the functional activity of the CD8+ MILs was assessed by IFNγ production following in vitro stimulation with irradiated CT-26 tumor cells, the immunodominant CT-26 tumor antigen (AH1), or saline (unstimulated). MILs from tumor immunized mice treated with saline, GMI-1271, and GMI-1359 were primed to respond to both AH1 and whole tumor cells. Unstimulated MILs from tumor immune mice or stimulated CD8+ T-cells from non-immune mice did not produce IFNγ. - The percent of CD8+ lymphocytes in peripheral blood armed to produce IFNγ was tested as well.
FIG. 3 illustrates that the percentage of CD8+ T-cells in peripheral blood primed to produce IFNγ was markedly increased following treatment with GMI-1271 or GM1-1359 but not saline or G-CSF. Without being bound to theory, applicant understands that these results are likely due to a redistribution of tumor-primed MILs into the blood compartment. - Thus, the experimental results here highlight a unique use of E-selectin antagonists, such as GMI-1271 (a compound of formula (I)) and GMI-1359 (a compound of formula (II)). The administration of E-selectin antagonists results in mobilization or redistribution of tumor-primed MILs into peripheral blood.
- The various embodiments described above can be combined to provide further embodiments. All U.S. patents, U.S. patent application publications, U.S. patent applications, non-U.S. patents, non-U.S. patent applications, and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary, to employ concepts of the various patents, applications, and publications to provide yet further embodiments.
- These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.
Claims (21)
1-19. (canceled)
21. The composition of claim 20 , wherein the at least one E-selectin antagonist is not used in combination with other agents used to mobilize hematopoietic stem cells.
22. The composition of claim 20 , wherein the MILs comprise CD8+ T cells.
23. The composition of claim 20 , wherein the MILs comprise naïve CD8+ T cells.
24. The composition of claim 20 , wherein the MILs comprise CD8+ T cells and wherein at least 5% of the CD8+ T cells are naïve CD8+ T cells.
25. The composition of claim 20 , wherein the MILs comprise CD8+ T cells and wherein at least 10% of the CD8+ T cells are naïve CD8+ T cells.
26. The composition of claim 20 , wherein the MILs comprise central memory CD8+ T cells.
27. The composition of claim 20 , wherein the MILs comprise CD8+ T cells and wherein at least 35% of the CD8+ T cells are central memory CD8+ T cells.
28. The composition of claim 20 , wherein the MILs comprise CD8+ T cells and wherein at least 40% of the CD8+ T cells are central memory CD8+ T cells.
29. The composition of claim 20 , wherein the MILs comprise both naïve CD8+ T cells and central memory CD8+ T cells.
30. The composition of claim 20 , wherein the MILs comprise CD8+ T cells and wherein at least 5% of the CD8+ T cells are naïve CD8+ T cells and at least 35% of the CD8+ T cells are central memory CD8+ T cells.
31. The composition of claim 20 , wherein the MILs comprise CD8+ T cells and wherein at least 10% of the CD8+ T cells are naïve CD8+ T cells and at least 40% of the CD8+ T cells are central memory CD8+ T cells.
32. The composition of claim 20 , wherein the MILs comprise CD8+ T cells armed to produce IFNγ following stimulation with a CT-26 tumor antigen.
33. The composition of claim 20 , wherein the MILs comprise CD8+ T cells and wherein at least 15% of the CD8+ T cells are armed to produce IFNγ following stimulation with a CT-26 tumor antigen.
34. The composition of claim 20 , wherein the MILs comprise CD8+ T cells and wherein at least 20% of the CD8+ T cells are armed to produce IFNγ following stimulation with a CT-26 tumor antigen.
35. The composition of claim 20 , wherein the MILs comprise CD8+ T cells and wherein at least 5% of the CD8+ T cells are naïve CD8+ T cells, at least 35% of the CD8+ T cells are central memory CD8+ T cells, and at least 15% of the CD8+ T cells armed to produce IFNγ following stimulation with a CT-26 tumor antigen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/327,429 US20230414642A1 (en) | 2017-11-30 | 2023-06-01 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592686P | 2017-11-30 | 2017-11-30 | |
PCT/US2018/062988 WO2019108750A1 (en) | 2017-11-30 | 2018-11-29 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
US202016767698A | 2020-05-28 | 2020-05-28 | |
US18/327,429 US20230414642A1 (en) | 2017-11-30 | 2023-06-01 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/767,698 Division US11712446B2 (en) | 2017-11-30 | 2018-11-29 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
PCT/US2018/062988 Division WO2019108750A1 (en) | 2017-11-30 | 2018-11-29 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230414642A1 true US20230414642A1 (en) | 2023-12-28 |
Family
ID=64744944
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/767,698 Active 2039-12-15 US11712446B2 (en) | 2017-11-30 | 2018-11-29 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
US18/327,429 Pending US20230414642A1 (en) | 2017-11-30 | 2023-06-01 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/767,698 Active 2039-12-15 US11712446B2 (en) | 2017-11-30 | 2018-11-29 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
Country Status (4)
Country | Link |
---|---|
US (2) | US11712446B2 (en) |
EP (1) | EP3717013A1 (en) |
JP (1) | JP7275131B2 (en) |
WO (1) | WO2019108750A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023529485A (en) * | 2020-06-14 | 2023-07-10 | グリコミメティクス, インコーポレイテッド | Compositions and methods for overcoming microenvironment-mediated resistance via E-selectin targeting |
Family Cites Families (246)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7409399A (en) | 1973-07-19 | 1975-01-21 | Rhone Poulenc Sa | PROCESS FOR THE PREPARATION OF THERMOSTABLE RESINS AND ARTICLES WHOLLY OR PARTIALLY CONSTITUTED FROM THESE RESINS. |
US4471057A (en) | 1981-06-30 | 1984-09-11 | The Wistar Institute | Detection of colorectal carcinoma |
DK17885D0 (en) | 1985-01-14 | 1985-01-14 | Karlsson Karl Anders | ANTIVIRAL AGENT |
US4876199A (en) | 1985-04-04 | 1989-10-24 | Fred Hutchinson Cancer Research Center | Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain |
US4851511A (en) | 1986-01-30 | 1989-07-25 | Fred Hutchinson Cancer Research Center | Monoclonal antibody that specifically binds to disialosyl Lea |
US4925796A (en) | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
ATE94395T1 (en) | 1986-05-09 | 1993-10-15 | Pulverer Gerhard | USE OF SPECIFIC MONOSACCHARIDS FOR THE MANUFACTURE OF A MEDICATION FOR THE PREVENTION OF METASTASIS OF MALIGNANT TUMORS. |
US5538724A (en) | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
US5079353A (en) | 1987-12-02 | 1992-01-07 | Chembiomed, Ltd. | Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation |
US5632991A (en) | 1988-11-14 | 1997-05-27 | Brigham & Women's Hospital | Antibodies specific for E-selectin and the uses thereof |
EP0381310A1 (en) | 1989-01-30 | 1990-08-08 | The Biomembrane Institute | Monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides and method for production thereof |
US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
EP0583799A1 (en) | 1989-05-23 | 1994-02-23 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies to ELAM-1 sialoglycoprotein antigen on the surface of activated endothelial cells |
US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US6001988A (en) | 1990-06-11 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US6280932B1 (en) | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
WO1991019501A1 (en) | 1990-06-15 | 1991-12-26 | Cytel Corporation | Intercellular adhesion mediators |
US5753631A (en) | 1990-06-15 | 1998-05-19 | Cytel Corporation | Intercellular adhesion mediators |
US5576305A (en) | 1990-06-15 | 1996-11-19 | Cytel Corporation | Intercellular adhesion mediators |
US6391857B1 (en) | 1990-06-18 | 2002-05-21 | Stanford University | Methods and compositions for endothelial binding |
US6387884B1 (en) | 1990-06-18 | 2002-05-14 | Stanford University | Leukocyte homing modulation |
DE69133120T2 (en) | 1990-07-17 | 2003-05-15 | Univ Oklahoma Norman Board Of | GMP-140 ligand |
US5143712A (en) | 1990-07-30 | 1992-09-01 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5648344A (en) | 1990-07-30 | 1997-07-15 | Glycomed Incorporated | Methods of treating inflammation using selection binding compounds |
US5211937A (en) | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
NZ240316A (en) | 1990-10-25 | 1996-12-20 | Univ Michigan | Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells |
NZ240646A (en) | 1990-11-23 | 1994-01-26 | Gen Hospital Corp | Therapeutic interference between cell adhesion proteins and their |
US5151360A (en) | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
US6124267A (en) | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
US6121233A (en) | 1991-04-19 | 2000-09-19 | John L. Magnani | Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules |
US5318890A (en) | 1991-05-06 | 1994-06-07 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
AU660995B2 (en) | 1991-05-06 | 1995-07-13 | Genentech Inc. | Glycam-1 (Sgp 50), a selectin ligand |
US5352670A (en) | 1991-06-10 | 1994-10-04 | Alberta Research Council | Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides |
US5580858A (en) | 1991-06-10 | 1996-12-03 | Alberta Research Council | Immunosuppressive and tolerogenic modified Lewisx compounds |
US5646123A (en) | 1991-06-10 | 1997-07-08 | Alberta Research Council | Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen |
EP0608260A1 (en) | 1991-09-10 | 1994-08-03 | Centocor, Inc. | Peptide inhibitors of inflammation mediated by selectins |
US5268364A (en) | 1991-12-12 | 1993-12-07 | The Biomembrane Institute | Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification |
AU3914393A (en) | 1991-12-18 | 1994-03-15 | Board Of Regents Of The University Of Oklahoma, The | Peptide inhibitors of inflammation mediated by selectins |
US5643873A (en) | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
US5591835A (en) | 1992-06-29 | 1997-01-07 | Glycomed Incorporated | Substituted lactose derivatives |
CA2100412A1 (en) | 1992-07-15 | 1994-01-16 | Yutaka Yamada | Glycolipid derivatives |
US5753617A (en) | 1992-09-08 | 1998-05-19 | Centocor, Inc. | Peptide inhibitors of cellular adhesion |
US5519008A (en) | 1992-09-10 | 1996-05-21 | Glycomed Incorporated | Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin) |
WO1994006442A1 (en) | 1992-09-11 | 1994-03-31 | The Regents Of The University Of California | Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation |
US5695752A (en) | 1992-09-11 | 1997-12-09 | The Regents Of The University Of California | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
EP0601417A3 (en) | 1992-12-11 | 1998-07-01 | Hoechst Aktiengesellschaft | Physiologically compatible and degradable polymer-based carbohydrate receptor blockers, a method for their preparation and their use |
US5710123A (en) | 1992-12-18 | 1998-01-20 | Centocor, Inc. | Peptide inhibitors of selectin binding |
ATE173630T1 (en) | 1992-12-29 | 1998-12-15 | Genentech Inc | TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH INTERFERON-GAMMA INHIBITORS |
US5412123A (en) | 1993-02-08 | 1995-05-02 | Glycomed Incorporated | Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system |
JP2716657B2 (en) | 1993-02-26 | 1998-02-18 | 株式会社ディ・ディ・エス研究所 | Compound having specific binding ability to adhesion molecule ELAM-1 |
WO1994020514A1 (en) | 1993-03-04 | 1994-09-15 | Mect Corporation | Lewis-associated compound, process for producing the same, and anti-inflammatory |
US5527890A (en) | 1993-04-16 | 1996-06-18 | Glycomed Incorporated | Derivatives of triterpenoid acids and uses thereof |
DE69326255T2 (en) | 1993-05-05 | 1999-12-30 | Affymax Tech Nv | ELAM-1 BINDING PEPTIDES AND COMPOSITIONS |
US5811404A (en) | 1993-05-14 | 1998-09-22 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
SE9301677L (en) | 1993-05-14 | 1994-11-18 | Kurt G I Nilsson | synthesis Method |
AU687408B2 (en) | 1993-05-14 | 1998-02-26 | Cytel Corporation | Sialyl LeX-analogues as inhibitors of cellular adhesion and methods for their preparation |
US5527785A (en) | 1993-05-14 | 1996-06-18 | The Regents Of The University Of California | Selectin receptor modulating compositions |
US5854218A (en) | 1993-05-14 | 1998-12-29 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
PT730608E (en) | 1993-05-17 | 2002-09-30 | Avant Immunotherapeutics Inc | COMPOSITIONS COMPOSING CARBON HYDRATES AND PROEINS RELATED BY THE COMPLEMENT AND METHODS FOR PRODUCING AND USING THE COMPOSITION REFERENCES |
US5856300A (en) | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5976540A (en) | 1993-05-17 | 1999-11-02 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5646248A (en) | 1993-06-08 | 1997-07-08 | La Jolla Cancer Research Foundation | E-selection binding soluble lamp-1 polypeptide |
US5789385A (en) | 1993-06-16 | 1998-08-04 | Glycomed Incorporated | Sialyl Lewisx mimetics containing phenyl backbones |
US5658880A (en) | 1993-06-16 | 1997-08-19 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5750508A (en) | 1993-06-16 | 1998-05-12 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5837689A (en) | 1993-06-16 | 1998-11-17 | Glycomed Incorporated | Sialyl lewis-x mimetics containing naphthyl backbones |
US5679321A (en) | 1993-06-17 | 1997-10-21 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
DK76193D0 (en) | 1993-06-25 | 1993-06-25 | Astra Ab | CARBOHYDRATE DERIVATIVES |
US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
US5508387A (en) | 1993-08-04 | 1996-04-16 | Glycomed Incorporated | Selectin binding glycopeptides |
US5827837A (en) | 1993-08-20 | 1998-10-27 | The Regents Of The University Of California | Polyanion anti-inflammatory agents |
US5464815A (en) | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
JPH09504522A (en) | 1993-10-12 | 1997-05-06 | グリコメド・インコーポレイテッド | Library of glyco-peptides useful for identifying cell adhesion inhibitors |
US5783693A (en) | 1993-11-19 | 1998-07-21 | The Regents Of The University Of California | Methods for synthesizing sulfated disaccharide inhibitors of selectins |
WO1995014787A1 (en) | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
US5663151A (en) | 1994-03-04 | 1997-09-02 | Bristol-Myers Squibb Company | Sulfated α-glycolipid derivatives as cell adhesion inhibitors |
DE4408248A1 (en) | 1994-03-11 | 1995-09-14 | Hoechst Ag | Physiologically acceptable and physiologically degradable carbohydrate mimetics, process for their preparation and their use |
EP0671409A3 (en) | 1994-03-11 | 1996-06-12 | Hoechst Ag | Malonic acid derivatives having anti-adhesive properties. |
US5444050A (en) | 1994-04-29 | 1995-08-22 | Texas Biotechnology Corporation | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa |
HUT77345A (en) | 1994-04-29 | 1998-03-30 | Texas Biotechnology Corporation | Mannopyranosyloxy biphenyl derivatives capable of inhibiting the binding of e-selectin,p-selectin or l-selectin to sialyl-lewis x or sialyl-lewis a and pharmaceutical compositions containing them |
US5486536A (en) | 1994-08-15 | 1996-01-23 | The Regents Of The University Of Michigan | Sulfatides as anti-inflammatory compounds |
JPH0899989A (en) | 1994-09-30 | 1996-04-16 | Akira Hasegawa | New glycolipid derivative and intermediate for its production |
DE4436164A1 (en) | 1994-10-10 | 1996-04-11 | Hoechst Ag | New conjugates of tetra:carbohydrate and amide-linked peptide or dye etc. |
US5686426A (en) | 1994-11-17 | 1997-11-11 | Bristol-Myers Squibb Company | Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors |
US6492332B1 (en) | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
US5639734A (en) | 1994-12-20 | 1997-06-17 | Esko; Jeffrey D. | Disaccharide inflammation inhibitors and uses thereof |
MX9704893A (en) | 1994-12-28 | 1997-10-31 | Sumitomo Pharma | Lewis x derivative and process for producing the same. |
US20020040008A1 (en) | 1995-01-24 | 2002-04-04 | Wagner Denisa D. | Method for treating and preventing atherosclerosis |
US5527936A (en) | 1995-02-17 | 1996-06-18 | E. I. Du Pont De Nemours And Company | Hydrosilylation of unsaturated compounds |
GB9504065D0 (en) | 1995-03-01 | 1995-04-19 | Pharmacia Spa | Poly-pyrrolecarboxamidonaphthalenic acid derivatives |
GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
AU6155896A (en) | 1995-06-07 | 1996-12-30 | Cytel Corporation | Humanized antibodies to e-selectin |
US5736533A (en) | 1995-06-07 | 1998-04-07 | Neose Technologies, Inc. | Bacterial inhibition with an oligosaccharide compound |
IT1290779B1 (en) | 1995-06-26 | 1998-12-10 | Antonio Sacchetti | PROCEDURE FOR THE ENHANCEMENT OF THE THERAPEUTIC ACTIVITIES OF NATURAL SUBSTANCES (VITAMINS, MINERALS, HERBS, PHYTO-PREPARATIONS, FOODS) |
BR9609285A (en) | 1995-06-29 | 1999-05-11 | Novartis Ag | Diglycosylated diols-1,2 as mimetics of sialyl-lewis x and sialyl-lewis a |
US5876715A (en) | 1995-08-17 | 1999-03-02 | The Biomembrane Institute | Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof |
DE19532902A1 (en) | 1995-09-06 | 1997-03-13 | Hoechst Ag | Novel glycomimetics as selectin antagonists and anti-inflammatory drugs made from them |
DE19537334A1 (en) | 1995-10-09 | 1997-04-10 | Hoechst Ag | New piperidine carboxylic acid and pyrrolidine carboxylic acid derivs. |
AU7445796A (en) | 1995-10-18 | 1997-05-07 | Cytel Corporation | Sialyl lex analogues as inhibitors of cellular adhesion |
US5919769A (en) | 1995-10-26 | 1999-07-06 | Kanebo, Ltd | Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same |
US5747463A (en) | 1995-11-13 | 1998-05-05 | Bristol-Myers Squibb Company | Malonate derivatives of glycolipids as cell adhesion inhibitors |
JPH09176047A (en) | 1995-12-25 | 1997-07-08 | Unitika Ltd | Medicinal composition for external use |
DE19602355A1 (en) | 1996-01-24 | 1997-07-31 | Hoechst Ag | Multiple fucosylated dicarboxylic acids with anti-adhesive properties |
AU1542397A (en) | 1996-01-30 | 1997-08-22 | Novartis Ag | Sialyl-lewisa and sialyl-lewisx epitope analogues |
WO1997028174A1 (en) | 1996-01-30 | 1997-08-07 | Novartis Ag | SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES |
US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
CA2247115C (en) | 1996-03-01 | 2008-11-18 | The Regents Of The University Of California | Inhibition of selectin binding |
US6344545B1 (en) | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
US5654412A (en) | 1996-05-29 | 1997-08-05 | Glycomed Incorporated | Processes for the synthesis of sialyl Lewisx compounds |
US5994402A (en) | 1996-06-05 | 1999-11-30 | Rotstein; Ori D. | Anti-inflammatory and anti-pyretic method |
US5919768A (en) | 1996-06-26 | 1999-07-06 | Texas Biotechnology Corporation | Di- and trivalent small molecule selectin inhibitors |
AU720381B2 (en) | 1996-08-08 | 2000-06-01 | Novartis Ag | Modified oligosaccharides |
US5830871A (en) | 1996-10-28 | 1998-11-03 | The Scripps Research Institute | Inhibitors of E-, P- and L-selectin binding |
GB9618520D0 (en) | 1996-09-05 | 1996-10-16 | Chiroscience Ltd | Compounds and their therapeutic use |
US6592872B1 (en) | 1996-09-17 | 2003-07-15 | The United States Of America As Represented By The Department Of Health And Human Services | Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein |
JP2001501612A (en) | 1996-09-27 | 2001-02-06 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Methods for treating ischemic disease and improving post-stroke symptoms |
US6110897A (en) | 1996-10-10 | 2000-08-29 | Glycorex Ab | Antiinflammatory cell adhesion inhibitors |
AU7180398A (en) | 1996-11-13 | 1998-06-03 | Morphogenesis, Inc. | Antibody MG1 recognizing a small subset of human hematopoietic cells |
WO1998037902A1 (en) | 1997-02-28 | 1998-09-03 | The Regents Of The University Of California | Inhibition of cell-cell binding by lipid assemblies |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
SE9701127D0 (en) | 1997-03-26 | 1997-03-26 | Karolinska Innovations Ab | Antigenic fusion protein carrying GALal, 3GAL epitopes |
JP3720520B2 (en) | 1997-03-27 | 2005-11-30 | タカラバイオ株式会社 | Method for measuring the interaction between sugar and target |
US6413760B1 (en) | 1997-04-15 | 2002-07-02 | Genetics Institute, Inc. | Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof |
US5916910A (en) | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
US6193973B1 (en) | 1997-08-22 | 2001-02-27 | B. David Tuttle | Dietary supplement for boosting energy and increasing muscular strength |
US5948628A (en) | 1997-09-05 | 1999-09-07 | The Board Of Regents Of The University Of Oklahoma | Methods of screening for compounds which mimic galectin-1 |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
WO1999043356A1 (en) | 1998-02-25 | 1999-09-02 | Hsc Research Development Limited Partnership | Antibiotic-ligand conjugates and methods of use thereof |
WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
CA2245224A1 (en) | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
US6458777B1 (en) | 1998-03-13 | 2002-10-01 | Mucosal Therapeutics Llc | Methods and compositions for treating and preventing mucositis |
US6365365B1 (en) | 1998-03-20 | 2002-04-02 | The Regents Of The University Of California | Method of determining whether an agent modulates glycosyl sulfotransferase-3 |
US6265192B1 (en) | 1998-03-20 | 2001-07-24 | The Regents Of The University Of California | Glycosly sulfortransferase-3 |
US6037333A (en) | 1998-05-07 | 2000-03-14 | Trustees Of Tufts College | Microbe-inhibiting compositions |
ES2347027T3 (en) | 1998-05-22 | 2010-10-22 | The Board Of Trustees Of The Leland Stanford Junior University | BIFUNCTIONAL MOLECULES AND THERAPIES BASED ON THE SAME. |
MXPA00012586A (en) | 1998-06-16 | 2004-05-21 | Univ Oklahoma | Glycosulfopeptides and methods of synthesis and use thereof. |
US6004815A (en) | 1998-08-13 | 1999-12-21 | The Regents Of The University Of California | Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells |
JP4553488B2 (en) | 1998-09-21 | 2010-09-29 | 大塚製薬株式会社 | Carboxymethyl galactose derivative |
US6960566B1 (en) | 1998-11-06 | 2005-11-01 | The Wister Institute of Anatomy and Biology | Compositions and methods for treatment of cancer |
IL142864A0 (en) | 1998-11-12 | 2002-03-10 | Novolytics Inc | Compositions and methods for producing vascular occlusion |
GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
WO2000066112A1 (en) | 1999-05-03 | 2000-11-09 | Smithkline Beecham Corporation | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6887842B1 (en) | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
US7204981B2 (en) | 2000-03-28 | 2007-04-17 | Eli Lilly And Company | Methods of treating diseases with activated protein C |
EP2345742B1 (en) | 2000-03-30 | 2014-06-11 | The Whitehead Institute for Biomedical Research | RNA sequence-specific mediators of RNA interference |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
WO2001089564A2 (en) | 2000-05-19 | 2001-11-29 | The Center For Blood Research, Inc. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
US20020165178A1 (en) | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
EP1325123A4 (en) | 2000-09-12 | 2004-07-21 | Inst Genetics Llc | Inhibition of stenosis or restenosis by p-selectin antagonists |
CA2423469A1 (en) | 2000-10-18 | 2002-04-25 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
CA2428721A1 (en) | 2000-11-14 | 2002-05-23 | The General Hospital Corporation | Blockade of t cell migration into epithelial gvhd target tissues |
US7422733B2 (en) | 2000-11-29 | 2008-09-09 | Bracco International B.V. | Linkable sialyl Lewis X analogs |
US20020132220A1 (en) | 2000-12-27 | 2002-09-19 | Berens Kurt L. | Use of selectin antagonists in organ preservation solutions |
BR0208474A (en) | 2001-03-28 | 2006-02-21 | Harvard College | method for providing a target antigen to a cell cytosol, isolated polypeptide, isolated dna, vector, pharmaceutical composition, methods for generating a median cell immune response in a mammal, producing a protein, and measuring a cell mediated immune response , and, Kit for measuring in vitro cell mediated immune responses |
US20030198639A1 (en) | 2002-04-16 | 2003-10-23 | Frenette Paul S. | Methods of treating sickle cell disease |
US7087212B2 (en) | 2001-08-17 | 2006-08-08 | Mallinckrodt, Inc | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
AU2002337913A1 (en) | 2001-10-19 | 2003-04-28 | Richard D. Cummings | Glycosulfopeptide inhibitors and methods of use thereof |
US20030211078A1 (en) | 2001-12-07 | 2003-11-13 | Heavner George A. | Pseudo-antibody constructs |
IL161784A0 (en) | 2001-12-21 | 2005-11-20 | Anormed Inc | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US20030186942A1 (en) | 2002-01-16 | 2003-10-02 | Crooks Peter A. | Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders |
EP1542704A1 (en) | 2002-04-18 | 2005-06-22 | Stephen H. Embury | Method and composition for preventing pain in sickle cell patients |
JP5183010B2 (en) | 2002-05-16 | 2013-04-17 | グリコミメティクス, インコーポレイテッド | Compounds and methods for inhibiting selectin-mediated functions |
AU2003245595A1 (en) | 2002-07-03 | 2004-01-23 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
AU2003282821B2 (en) | 2002-10-11 | 2010-12-16 | University Of Maryland, Baltimore | Carbohydrate-based synthetic vaccines for HIV |
AU2003301209A1 (en) | 2002-12-20 | 2004-07-22 | Glycomimetics, Inc. | Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection |
US6844125B2 (en) | 2003-03-20 | 2005-01-18 | Kabushiki Kaisha Toshiba | Combination of developing agents, image forming apparatus, and method for forming image |
US7332334B2 (en) | 2003-04-18 | 2008-02-19 | Oklahoma Medical Research Foundation | Hematopoietic stem cells treated by in vitro fucosylation and methods of use |
US20040219158A1 (en) | 2003-05-02 | 2004-11-04 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
US7041226B2 (en) | 2003-11-04 | 2006-05-09 | Lexmark International, Inc. | Methods for improving flow through fluidic channels |
CA2544598A1 (en) | 2003-11-07 | 2005-05-26 | Brigham And Women's Hospital, Inc. | Antibodies to cd44 glycoforms and uses thereof |
ATE383367T1 (en) | 2003-11-19 | 2008-01-15 | Glycomimetics Inc | SPECIFIC ANTAGONIST FOR BOTH E- AND P-SELECTINS |
US20050187171A1 (en) | 2003-11-19 | 2005-08-25 | Glycomimetics, Inc. | Glycomimetic antagonists for both E-and P-selectins |
EP1709063B1 (en) | 2003-12-18 | 2008-01-23 | Unibioscreen S.A. | Glycosylated steroid derivatives with anti-migratory activity |
GB0404434D0 (en) | 2004-02-27 | 2004-03-31 | Novartis Ag | Organic compounds |
WO2005116088A2 (en) | 2004-05-25 | 2005-12-08 | The Johns Hopkins University | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells |
WO2006002382A2 (en) | 2004-06-24 | 2006-01-05 | The Scripps Research Institute | Arrays with cleavable linkers |
WO2006017180A2 (en) | 2004-07-09 | 2006-02-16 | Progenics Pharmaceuticals, Inc. | Glycopeptide dimers and uses thereof |
JP5135795B2 (en) | 2004-08-27 | 2013-02-06 | 小野薬品工業株式会社 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF |
WO2006062946A2 (en) | 2004-12-06 | 2006-06-15 | University Of Florida Research Foundation, Inc. | Incorporation of bone marrow derived stem cells in tumors |
CA2593612A1 (en) | 2005-01-07 | 2006-07-13 | Emory University | Cxcr4 antagonists for the treatment of hiv infection |
WO2006074428A2 (en) | 2005-01-07 | 2006-07-13 | Emory University | Cxcr4 antagonists for the treatment of medical disorders |
AU2006214190A1 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
US20060217303A1 (en) | 2005-03-25 | 2006-09-28 | Wisconsin Alumni Research Foundation | Compounds and Methods for Treating Seizure Disorders |
US20090036386A1 (en) | 2005-05-25 | 2009-02-05 | Glycomimetics, Inc | Heterobifunctional compounds for selectin inhibition |
US20060287253A1 (en) | 2005-06-17 | 2006-12-21 | Kriegler Steven M | Compounds and methods for treating seizure disorders |
CN101583273A (en) | 2005-07-22 | 2009-11-18 | 加利福尼亚大学董事会 | Heparin compostions and selectin inhibition |
CA2618638C (en) | 2005-08-09 | 2014-03-11 | Glycomimetics, Inc. | Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
BRPI0614865A2 (en) | 2005-08-15 | 2011-04-19 | Scripps Research Inst | methods for identifying therapeutic agents and danisil derivatives |
WO2007022385A2 (en) | 2005-08-18 | 2007-02-22 | Novartis Ag | Use of cxcr4 binding molecules for the treatment of whim syndrome |
SI2264043T1 (en) | 2005-09-02 | 2018-01-31 | Glycomimetics, Inc. | Heterobifunctional pan-selectin inhibitors |
WO2007033329A1 (en) | 2005-09-14 | 2007-03-22 | University Of Maryland Biotechnology Institute Off. Of Research Admin./ Tech.Dev. | Synthetic polyvalent carbohydrates as components of microbicides |
WO2007143052A1 (en) | 2006-06-01 | 2007-12-13 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
EP3042668B1 (en) | 2006-06-07 | 2018-09-19 | The Board of Trustees of the Leland Stanford Junior University | Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
US20090175792A1 (en) | 2006-06-23 | 2009-07-09 | Glycomimetics, Inc. | Glycomimetic inhibitors of siglec-8 |
US20080227799A1 (en) | 2006-07-11 | 2008-09-18 | Liotta Dennis C | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders |
WO2008008852A2 (en) | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
WO2008008854A2 (en) | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders |
US7998740B2 (en) | 2006-07-18 | 2011-08-16 | Robert Sackstein | Cytokine induction of selectin ligands on cells |
WO2008060378A2 (en) | 2006-10-12 | 2008-05-22 | Glycomimetics, Inc. | Glycomimetic replacements for hexoses and n-acetyl hexosamines |
US20080306098A1 (en) | 2006-11-06 | 2008-12-11 | Mutz Mitchell W | Pharmacokinetics of protease inhibitors and other drugs |
US20100145032A1 (en) | 2007-01-18 | 2010-06-10 | Suomen Punainen Risti, Veripalelu | Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof |
EP2457573A1 (en) | 2007-02-09 | 2012-05-30 | GlycoMimetics, Inc. | Methods of use of glycomimetics with replacements for hexoses and N-Acetyl hexosamines |
US20080261978A1 (en) | 2007-03-08 | 2008-10-23 | Clark Michael P | Chemokine receptor modulators |
US20090054334A1 (en) | 2007-05-23 | 2009-02-26 | Mutz Mitchell W | Combinatorial improvement of bifunctional drug properties |
US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
KR20100042654A (en) | 2007-08-08 | 2010-04-26 | 교와 핫꼬 기린 가부시키가이샤 | Isolated cell mass |
CN101918041A (en) | 2007-10-12 | 2010-12-15 | 超分子有限公司 | The systemic administration that is used for the catilan agent of diagnosing tumor and treatment |
FI20070853A0 (en) | 2007-11-09 | 2007-11-09 | Glykos Finland Oy | Glycan binding monoclonal antibodies |
WO2009073911A1 (en) | 2007-12-10 | 2009-06-18 | Mater Medical Research Institute | Treatment and prophylaxis |
WO2009126556A1 (en) | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
WO2009152245A1 (en) | 2008-06-13 | 2009-12-17 | Glycomimetics, Inc. | Treatment of cancers of the blood using selected glycomimetic compounds |
US20110245265A1 (en) | 2008-08-29 | 2011-10-06 | Genzyme Corporation | Cxcr4 antagonists for kidney injury |
US20100240773A1 (en) | 2009-03-23 | 2010-09-23 | Kenneth Korzekwa | Multifunctional linkers |
FI20095459A0 (en) | 2009-04-24 | 2009-04-24 | Suomen Punainen Risti Veripalv | New Assay Methods |
JP5726171B2 (en) | 2009-05-01 | 2015-05-27 | グリコミメティックス インコーポレイテッド | Heterobifunctional inhibitors of E-selectin and CXCR4 chemokine receptors |
US20120093782A1 (en) | 2009-05-13 | 2012-04-19 | Grove Robert I | Enhanced Hematopoietic Stem Cell Engraftment |
WO2011127179A1 (en) | 2010-04-07 | 2011-10-13 | Glycomimetics, Inc. | Glycomimetic compounds and methods to inhibit infection by hiv |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
US20130261070A1 (en) | 2010-10-04 | 2013-10-03 | John L. Magnani | Anti-epileptogenic agents |
FI20106031A0 (en) | 2010-10-06 | 2010-10-06 | Suomen Punainen Risti Veripalv | Method of isolating cells and cell population isolated by the method |
WO2012061662A1 (en) | 2010-11-03 | 2012-05-10 | Glycomimetics, Inc. | Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors |
US8765126B2 (en) * | 2011-05-05 | 2014-07-01 | Robert Sackstein | Methods of treating complications and disorders associated with G-CSF administration |
CA2858099C (en) * | 2011-12-22 | 2020-12-15 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
EP2914610A2 (en) | 2012-10-31 | 2015-09-09 | GlycoMimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
WO2014089269A1 (en) | 2012-12-07 | 2014-06-12 | Glycomimetics, Inc. | Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells |
WO2014149837A1 (en) | 2013-03-15 | 2014-09-25 | Glycomimetics, Inc. | Compounds and methods to enhance the oral availability of glycomimetics |
JP2016527303A (en) | 2013-08-05 | 2016-09-08 | ケンブリッジ エンタープライズ リミテッド | Inhibition of CXCR4 signaling in cancer immunotherapy |
AU2014324634A1 (en) | 2013-09-30 | 2016-04-14 | Glycomimetics, Inc. | Methods and compositions for treating and/or preventing mucositis |
US20160333043A1 (en) | 2014-01-17 | 2016-11-17 | Glycomimetics, Inc. | E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose |
WO2016089872A1 (en) | 2014-12-03 | 2016-06-09 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
WO2016164394A1 (en) | 2015-04-08 | 2016-10-13 | Glycomimetics, Inc. | 2-halo-galactose-containing selectin antagonists |
JP2018522040A (en) | 2015-08-03 | 2018-08-09 | グリコミメティクス, インコーポレイテッド | Method for mobilization and use of T cells with enhanced reconstitution and longevity |
WO2017095904A1 (en) | 2015-12-02 | 2017-06-08 | Glycomimetics, Inc. | Heterobifunctional pan-selectin antagonists having a triazole linker |
WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
EP3497131B1 (en) | 2016-08-08 | 2022-03-09 | GlycoMimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4. |
US11072625B2 (en) | 2016-10-07 | 2021-07-27 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
JP7272956B2 (en) * | 2017-03-15 | 2023-05-12 | グリコミメティクス, インコーポレイテッド | Galactopyranosyl-cyclohexyl derivatives as E-selectin antagonists |
CN114401726A (en) * | 2019-07-31 | 2022-04-26 | 糖模拟物有限公司 | Use of E-selectin antagonists to improve survival of reconstituted bone marrow depleted hosts |
-
2018
- 2018-11-29 WO PCT/US2018/062988 patent/WO2019108750A1/en unknown
- 2018-11-29 JP JP2020529351A patent/JP7275131B2/en active Active
- 2018-11-29 EP EP18822193.1A patent/EP3717013A1/en active Pending
- 2018-11-29 US US16/767,698 patent/US11712446B2/en active Active
-
2023
- 2023-06-01 US US18/327,429 patent/US20230414642A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210177878A1 (en) | 2021-06-17 |
WO2019108750A1 (en) | 2019-06-06 |
US11712446B2 (en) | 2023-08-01 |
EP3717013A1 (en) | 2020-10-07 |
JP2021504403A (en) | 2021-02-15 |
JP7275131B2 (en) | 2023-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220000867A1 (en) | Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination | |
US10993956B2 (en) | GLA monotherapy for use in cancer treatment | |
US20230127765A1 (en) | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4 | |
US10821127B2 (en) | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient | |
US11918558B2 (en) | Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia | |
US20080226674A1 (en) | Composition Having Antitumor Effect | |
US20230414642A1 (en) | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof | |
CZ31696A3 (en) | The use of triphenylethylene antiestrogens for increasing sensitivity of cancer cells for lysis mediated through killing cells | |
US20080096841A1 (en) | Treatment and Prevention of Heat Shock Protein-Associated Diseases and Conditions | |
KR20180041229A (en) | Methods for stem cell transplantation | |
US20150087615A1 (en) | Compositions and methods for reducing or preventing metastasis | |
Okita et al. | Targeting of CD4+ CD25high cells while preserving CD4+ CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer | |
US20200170970A1 (en) | Ceramide nanoliposomes, compositions and methods of using for immunotherapy | |
US8163702B2 (en) | Treatment of melanoma | |
Dyevoich et al. | Type I IFN, Ly6C+ cells, and phagocytes support suppression of peritoneal carcinomatosis elicited by a TLR and CLR agonist combination | |
US9101558B2 (en) | Use of anti-cancer cell composition for treatment of head and neck cancer, which is intended to be administered to nutrient artery of tumor | |
EP3000471A1 (en) | Novel immunostimulatory molecules | |
CN117323428A (en) | Application of natural sugar molecule Xu5P as tumor immunotherapy adjuvant | |
Reil | VAX014 Efficacy in the B16F10 Mouse Melanoma Model: A Novel Oncolytic Immunotherapy for Melanoma | |
WO2023230212A1 (en) | Combination treatment for adenocarcinoma | |
CN117100854A (en) | Application of sertraline combined with PD-1 monoclonal antibody and pharmaceutical composition | |
CN113769096A (en) | Medical application of 6-phosphoglucose dehydrogenase inhibitor | |
Prescott | New growth factors spurt into action |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLYCOMIMETICS, INC., MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAGNANI, JOHN L.;FOGLER, WILLIAM E.;SIGNING DATES FROM 20181022 TO 20181023;REEL/FRAME:063949/0976 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |